var title_f21_54_22368="Adjustable gastric band";
var content_f21_54_22368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adjustable gastric band",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laparoscopic gastric banding is a purely restrictive procedure that compartmentalizes the upper stomach by placing a tight, adjustable prosthetic band around the entrance to the stomach. The gastric band consists of a soft, locking silicone ring connected to an infusion port placed in the subcutaneous tissue. The port may be accessed with relative ease by a syringe and needle. Injection of saline into the port leads to reduction in the band diameter, resulting in an increased degree of restriction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22368=[""].join("\n");
var outline_f21_54_22368=null;
var title_f21_54_22369="Radiograph of ectopic ureter";
var content_f21_54_22369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiograph of ectopic ureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Dye injected via spinal needle (arrow) placed in the suprapubic area under cystoscopic visualization, illustrating left ectopic ureter (B) and extention down the vaginal wall to introitus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22369=[""].join("\n");
var outline_f21_54_22369=null;
var title_f21_54_22370="CT dilated small intestine";
var content_f21_54_22370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction CT (coronal images)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel obstruction seen by CT scan (coronal images) showing dilated, fluid-filled loops of small intestine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Hodin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22370=[""].join("\n");
var outline_f21_54_22370=null;
var title_f21_54_22371="Nausea and vomiting in infants and children";
var content_f21_54_22371=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/54/22371/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22371/contributors\" id=\"au3615\">",
"       Carlo Di Lorenzo, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/54/22371/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22371/contributors\" id=\"se5192\">",
"       George D Ferry, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/54/22371/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22371/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/54/22371?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Nausea and vomiting are common in children, and are usually part of a mild, short-lived illness, frequently caused by a viral infection.",
"    </p>",
"    <p>",
"     Although most children recover from nausea and vomiting without any treatment, it is important to know when to seek help if the child does not get better.",
"    </p>",
"    <p>",
"     Spitting up in infants (gastroesophageal reflux) is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY DOES VOMITING OCCUR?",
"     </span>",
"    </p>",
"    <p>",
"     Vomiting occurs when nerves in the body or brain sense a trigger, such as food poisoning, certain infections or medicines, or motion. Nausea sometimes, but not always, occurs before vomiting. Younger children may not be able to describe nausea, although they may complain of a stomach ache or have other general complaints.",
"    </p>",
"    <p>",
"     Vomiting often has a benefit since it provides a way for the body to get rid of potentially harmful substances. However, medicines and methods to induce vomiting (eg, syrup of ipecac, placing a finger in the throat) are no longer recommended, even if an infant or child has ingested a harmful substance. In this case, it is best to immediately call for emergency medical assistance, available in the United States by calling 911.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Vomit versus spit up",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a difference between vomiting and spitting up, although the terms are often used interchangeably. Spitting up often occurs with a burp after feeding. The medical term for this is gastroesophageal reflux (GER). Most infants spit up milk or formula through the mouth or nose. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      CAUSES OF VOMITING",
"     </span>",
"    </p>",
"    <p>",
"     Vomiting can be caused by a number of different problems. The possible causes of vomiting depend upon a child's age.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Newborns and young infants",
"     </span>",
"     &nbsp;&mdash;&nbsp;It can be hard to tell if an infant is spitting up or vomiting because some infants reflux forcefully or in large amounts. Your child's doctor or nurse can help to determine the cause and if treatment is needed.",
"    </p>",
"    <p>",
"     Forceful vomiting in newborns can indicate a serious condition and always requires further evaluation. Potential causes of vomiting in newborns and young infants include a blockage or narrowing of the stomach (pyloric stenosis) or a blockage of the intestines (intestinal obstruction).",
"    </p>",
"    <p>",
"     Infants can also vomit because of infections of the intestine or other parts of the body. Any young infant (newborn to 3 months) who develops a temperature of 100.4&ordm; F (38&ordm; C) or higher, with or without vomiting, should see a doctor or nurse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Older infants and children",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common cause of vomiting in older infants and children is infectious gastroenteritis (an infection of the stomach or intestines), usually caused by a virus. Vomiting caused by gastroenteritis usually begins suddenly and resolves quickly, often within 24 hours. Other signs of gastroenteritis can include nausea, diarrhea, fever, or abdominal pain. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Gastroenteritis can develop after eating contaminated food or putting a contaminated object (or hand) into the mouth. The viruses that commonly cause gastroenteritis are spread easily. Careful hygiene (especially hand washing) can prevent these infections from spreading.",
"    </p>",
"    <p>",
"     Less commonly, vomiting occurs after consuming improperly stored or prepared foods that contain bacteria or toxins; this is called food poisoning. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"      \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other illnesses can also cause vomiting in older infants and children, including gastroesophageal reflux, peptic ulcer disease, an intestinal blockage (obstruction), and others. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Adolescents",
"     </span>",
"     &nbsp;&mdash;&nbsp;Similar to children, the most common cause of nausea and vomiting in adolescents is infectious gastroenteritis. Vomiting usually resolves within 24 to 48 hours in an adolescent with gastroenteritis.",
"    </p>",
"    <p>",
"     Less common causes of vomiting in adolescents include appendicitis (inflammation of the appendix), induced vomiting (eg, as seen with bulimia), pregnancy, gastric ulcers (of the stomach), pancreatitis (inflammation of the pancreas), inflammatory bowel disease (eg, Crohn's disease), and consumption of toxic substances (eg, overdose).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      NAUSEA AND VOMITING DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Most children with vomiting do not need to be seen by a healthcare provider. However, you should monitor for signs that the child is getting worse or not getting better within 24 hours. If your child has severe pain or has signs of dehydration, they should be seen sooner. If you are concerned about your child, call the child's doctor or nurse (see",
"     <a class=\"local\" href=\"#H18\">",
"      'When to seek help'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     If the child sees a doctor or nurse, he or she will review the child's medical history, perform an exam, and if needed, perform testing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      HOME CARE OF NAUSEA AND VOMITING",
"     </span>",
"    </p>",
"    <p>",
"     The following are some simple recommendations to help care for children with nausea and vomiting at home.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Monitor for dehydration",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dehydration can develop in children with vomiting.",
"    </p>",
"    <p>",
"     Signs of mild dehydration include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A slightly dry mouth",
"      </li>",
"      <li>",
"       Thirst",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Children who are mildly dehydrated do not need immediate medical attention but should be monitored for signs of worsening dehydration.",
"    </p>",
"    <p>",
"     Signs of moderate or severe dehydration include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Decreased urination (not going to the bathroom or no wet diaper in 6 hours)",
"      </li>",
"      <li>",
"       A lack of tears when crying",
"      </li>",
"      <li>",
"       A dry mouth",
"      </li>",
"      <li>",
"       Sunken eyes",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A child who is moderately or severely dehydrated should be evaluated by a doctor or nurse as soon as possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Dietary recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children who are vomiting but are not dehydrated can continue to eat a regular diet as tolerated. Dehydrated children require rehydration (replacement of lost fluid). (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Oral rehydration therapy'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Infants",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a breastfeeding infant vomits, he or she should continue to breastfeed unless your doctor or nurse tells you otherwise. Oral rehydration solutions (eg, Pedialyte&reg;) are not usually needed for infants who exclusively breastfeed because breastmilk is more easily digested. If your infant vomits immediately after nursing, you can try to breastfeed more frequently and for a shorter time.",
"    </p>",
"    <p>",
"     For example, breastfeed every 30 minutes for five to 10 minutes. If vomiting improves after two to three hours, resume the usual feeding schedule. If vomiting worsens or does not improve within 24 hours, call your child's doctor or nurse (see",
"     <a class=\"local\" href=\"#H18\">",
"      'When to seek help'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     If your infant drinks formula, initially offer one to two ounces of an oral rehydration solution (eg, Pedialyte&reg;) every 30 minutes for two to three hours. If vomiting improves, resume feeding with full strength infant formula. If vomiting worsens or does not improve within 24 hours, call your child's doctor or nurse (see",
"     <a class=\"local\" href=\"#H18\">",
"      'When to seek help'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Older infants and children",
"     </span>",
"     &nbsp;&mdash;&nbsp;Older infants and children who vomit can continue to eat, if desired. However, it is common for children to have little or no appetite during a vomiting illness.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Monitor for signs of dehydration, and do not force the child to eat, especially during the first 24 hours. Encourage the child to drink fluids. The best fluids are the commercially prepared oral rehydration solutions (eg, Pedialyte&reg;) (see",
"       <a class=\"local\" href=\"#H14\">",
"        'Oral rehydration therapy'",
"       </a>",
"       below). Other fluids, including water, diluted juice, or soda can be given in small quantities.",
"      </li>",
"      <li>",
"       Apple, pear, and cherry juice, and other beverages with high sugar content, should be avoided. Sports drinks (eg, Gatorade) should also be avoided since they have too much sugar and have inappropriate electrolyte levels.",
"      </li>",
"      <li>",
"       Recommended foods include a combination of complex carbohydrates (rice, wheat, potatoes, bread), lean meats, yogurt, fruits, and vegetables. High fat foods are more difficult to digest, and should be avoided.",
"      </li>",
"      <li>",
"       It is not necessary to restrict a child's diet to clear liquids or the BRAT diet (bananas, rice, applesauce, toast). Although these and similar foods might be recommended to decrease diarrhea, these foods do not contain enough nutrients for a child.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Oral rehydration therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral rehydration therapy (ORT) was developed as a safer, less-expensive, and easier alternative to intravenous (IV) fluids. Oral rehydration solution (ORS) is a liquid solution that contains glucose (a sugar) and electrolytes (sodium, potassium, chloride), which are lost with vomiting and diarrhea.",
"    </p>",
"    <p>",
"     ORS does not cure vomiting, but it does help to prevent and treat the dehydration that can develop because of a vomiting illness. You can buy ORS at most grocery stores and pharmacies in the United States without a prescription. A few widely available brands include Pedialyte&reg;, Infalyte&reg;, and ReVital&reg;, although generic brands work equally well (",
"     <a class=\"graphic graphic_table graphicRef70752 \" href=\"UTD.htm?13/24/13708\">",
"      table 1",
"     </a>",
"     ). Gelatin, tea, fruit juice, rice water, and other beverages are not recommended in children who are dehydrated. Do not try to prepare ORS recipes at home because the formulas must be exact.",
"    </p>",
"    <p>",
"     You can give ORS at home if your child is mildly dehydrated, refusing to eat a normal diet, or has vomiting, diarrhea, or both. If needed, you can give ORS in frequent, small sips or small amounts by spoon, bottle, or cup over three to four hours. Your child's doctor or nurse might provide specific instructions for giving oral rehydration. One method is described below:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The recommended amount is 5 teaspoons per pound, or 50 milliliters per kilogram (",
"       <a class=\"graphic graphic_table graphicRef62163 \" href=\"UTD.htm?31/15/31995\">",
"        table 2",
"       </a>",
"       ). For a 20-pound (9 kg) child, this would equal 100 teaspoons (450 milliliters).",
"      </li>",
"      <li>",
"       Measure the solution with a standardized medicine syringe or measuring cup or spoon, rather than a regular cup or spoon.",
"      </li>",
"      <li>",
"       Give the fluid by teaspoonfuls (5 milliliters each) every one to two minutes or as tolerated.",
"      </li>",
"      <li>",
"       After you give the whole amount, the child can eat a normal diet.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Children who refuse to drink or who vomit immediately after drinking ORS should be monitored closely for worsening dehydration. Children who are not dehydrated can continue to drink ORS between episodes of vomiting to prevent dehydration. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Monitor for dehydration'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medicines to reduce nausea and vomiting, called antiemetics, might be recommended in certain situations (to reduce the risk of dehydration in children who vomit repeatedly or to prevent motion sickness). These medicines require a prescription, and you should not give them to an infant or child unless your child's doctor or nurse has recommended them. Non-prescription treatments for nausea or vomiting are not recommended for infants or children.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Preventing spread",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your child is vomiting, you need to be careful to avoid spreading the infection to yourself, your family, and friends. Wash your hands frequently and keep sick children out of school or daycare. Children with vomiting (two or more times in 24 hours) that is caused by a contagious condition should be kept out of school or daycare until they have not vomited for 24 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Hygiene measures",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hand washing is an essential and very effective way to prevent the spread of infection. Wet your hands with water and plain or antimicrobial soap, and rub them together for 15 to 30 seconds. Pay special attention to the fingernails, between the fingers, and the wrists. Rinse your hand thoroughly, dry them with a paper towel, and throw away the paper towel.",
"    </p>",
"    <p>",
"     Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available. Spread the hand rub over the entire surface of your hands, fingers, and wrists until dry. You can use the rub over and over, if needed. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. If you hands are visibly dirty, you should wash them with soap and water.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     You should call your doctor or nurse",
"     <strong>",
"      immediately",
"     </strong>",
"     if your child has any of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bile (green) or blood-tinged (red or brown) vomit",
"      </li>",
"      <li>",
"       Any episode of vomiting in a newborn, or vomiting that continues for more than 24 hours in an infant or child",
"      </li>",
"      <li>",
"       If an infant refuses to eat or drink anything for more than a few hours",
"      </li>",
"      <li>",
"       Moderate to severe dehydration: dry mouth, no tears when crying, not urinating or having a wet diaper in four to six hours (for babies and young children) or not urinating in six to eight hours (for older children).",
"      </li>",
"      <li>",
"       Abdominal pain that is severe, even if it comes and goes",
"      </li>",
"      <li>",
"       Fever higher than 102&ordm;F (39&ordm;C) once or fever higher than 101&ordm;F (38.4&ordm;C) for more than three days",
"      </li>",
"      <li>",
"       Behavior changes, including lethargy or decreased responsiveness",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1785031039\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518951\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/37/3666?source=see_link\">",
"      Patient information: Appendicitis in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=see_link\">",
"      Patient information: Motion sickness (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/27/26033?source=see_link\">",
"      Patient information: Pyloric stenosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518959\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/50/32547?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24521?source=see_link\">",
"      Approach to the infant or child with nausea and vomiting",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34568?source=see_link\">",
"      Cyclic vomiting syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/29/3545?source=see_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"      Oral rehydration therapy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Centers for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www2.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aap.org\">",
"      www.aap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/54/22371/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/54/22371?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22371/abstract/1\">",
"      Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev 2011; :CD005506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22371/abstract/2\">",
"      Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; :CD004125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22371/abstract/3\">",
"      Hartling L, Bellemare S, Wiebe N, et al. Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst Rev 2006; :CD004390.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Children in out-of-home child care. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, et al.  (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.133.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_54_22371=[""].join("\n");
var outline_f21_54_22371=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY DOES VOMITING OCCUR?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           CAUSES OF VOMITING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           NAUSEA AND VOMITING DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           HOME CARE OF NAUSEA AND VOMITING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?13/24/13708\" title=\"table 1\">",
"           ORS other bev PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?31/15/31995\" title=\"table 2\">",
"           ORT replacement guide PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22372="Actinic keratosis hand";
var content_f21_54_22372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratosis. Scale overlies erythematous macules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22372=[""].join("\n");
var outline_f21_54_22372=null;
var title_f21_54_22373="Microbiology and pathogenesis of Yersinia infections";
var content_f21_54_22373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and pathogenesis of Yersinia infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Robert V Tauxe, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22373/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/54/22373/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H102678491\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Yersinia includes 11 species, three of which are important human pathogens: Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/1\">",
"     1",
"    </a>",
"    ]. The yersinioses are zoonotic infections of domestic and wild animals; humans are considered incidental hosts that do not contribute to the natural disease cycle.",
"   </p>",
"   <p>",
"    Y. enterocolitica and Y. pseudotuberculosis cause yersiniosis, a diarrheal illness. The microbiological characteristics, pathogenic determinants and laboratory isolation and characterization of Y. enterocolitica and Y. pseudotuberculosis will be reviewed here. The epidemiology, clinical manifestations and treatment of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=see_link\">",
"     \"Epidemiology of yersiniosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Y. pestis causes plague and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102678527\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Members of the genus Yersinia are gram-negative coccobacilli; they are facultative anaerobes in the family Enterobacteriaceae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/2\">",
"     2",
"    </a>",
"    ]. Like other Enterobacteriaceae, Y. pseudotuberculosis and Y. enterocolitica are bile tolerant and grow on MacConkey agar, they ferment glucose but not lactose, they are oxidase-negative, and reduce nitrate to nitrite.",
"   </p>",
"   <p>",
"    Y. pseudotuberculosis and Y. enterocolitica are readily differentiated by biochemical tests. Y. enterocolitica ferments sucrose and Y. pseudotuberculosis does not, while Y. pseudotuberculosis ferments rhamnose and melibiose and Y. enterocolitica does not. Yersinia enterocolitica can be further subtyped into biotypes by a combination of phenotypic markers [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/3\">",
"     3",
"    </a>",
"    ]. They can also be serogrouped using antisera produced against cell surface lipopolysaccharide antigens, known classically as the O antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For Y. enterocolitica, biogroup and serotype are correlated. The most common are serotype O:9 biotype 2, serotype O:3 biotype 4 and serotype O:8 biotype 1B [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/5\">",
"     5",
"    </a>",
"    ]. A similar serotyping system exists for Y. pseudotuberculosis. Both Y. enterocolitica and Y. pseudotuberculosis can be further subtyped using molecular methods such as pulsed field gel electrophoresis.",
"   </p>",
"   <p>",
"    Yersinia enterocolitica exhibits three noteworthy microbiological features. It is psychrophilic, which means that on suitable media it is capable of multiplying at refrigerator temperatures (although its optimum growth temperature is 25 to 28&deg;C). Second, most strains lack efficient intrinsic iron uptake mechanisms, and depend on the iron binding strategies of other bacteria to capture the iron that they need [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/6\">",
"     6",
"    </a>",
"    ]. Conditions associated with iron-overload such as chronic liver disease, hemochromatosis, and thalassemias have been associated with an increased risk of invasive yersiniosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/7\">",
"     7",
"    </a>",
"    ]. Third, many virulent strains are relatively calcium dependent, and require calcium-supplemented medium to grow at 37&deg;C.",
"   </p>",
"   <p>",
"    Certain subtypes of Yersinia enterocolitica are considered virulent for humans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/8\">",
"     8",
"    </a>",
"    ]. Isolation of non-virulent types from a non-sterile body site is likely to be an incidental finding. Rapid tests can determine whether an isolate is likely to be pathogenic (see below).",
"   </p>",
"   <p>",
"    Subtyping by serotyping and molecular methods is of epidemiological utility. Biotype and serogroup can provide a clue to the environmental source of an infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/2\">",
"     2",
"    </a>",
"    ]. A cluster of infections of the same subtype may indicate that the cases are linked to a common source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3697194\">",
"    <span class=\"h2\">",
"     Laboratory isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory identification depends on isolation of the organism via bacteriologic culture. Most laboratories in North America do not routinely screen for Yersinia species, and the organism grows poorly on the Salmonella-Shigella and Campylobacter agars commonly used for the isolation of stool pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/4\">",
"     4",
"    </a>",
"    ]. Yersinia grows well on MacConkey agar, but at routine incubation temperatures it forms small colorless lactose-negative colonies, which are easily overlooked by the inexperienced eye unless plates are specifically examined for them [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective growth medium is recommended in laboratories not familiar with the appearance of the colonies. The most widely studied is cefsulodin-irgasin-novobiocin (CIN) agar, which inhibits the growth of competing flora and produces a characteristic colony morphology (",
"    <a class=\"graphic graphic_figure graphicRef64722 \" href=\"UTD.htm?2/22/2405\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/9\">",
"     9",
"    </a>",
"    ]. The optimal growth temperature for Yersinia species is 25 to 28&deg;C, which also inhibits the growth of other organisms, even on non-selective MacConkey agar. The organism can be isolated at this temperature within 24 to 48 hours. If a clinician specifically requests Yersinia culture, the laboratory will usually either use CIN media or reincubate the original MacConkey agar culture.",
"   </p>",
"   <p>",
"    The use of a cold enrichment step at 4&deg;C can facilitate recovery of Yersinia enterocolitica when the bacterial density is low, such as in the convalescent phase of an infection. However, this procedure is likely to lead to isolation of non-pathogenic strains, and may require incubation for weeks, limiting clinical use. Isolates of Yersinia enterocolitica identified in this fashion must be further characterized before diagnostic conclusions are drawn.",
"   </p>",
"   <p>",
"    In addition to biotype and serotype determination, several rapid tests have been developed to identify pathogenic strains. They are highly specific and sensitive for fresh isolates, although the virulence plasmid can be lost when strains are stored [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of pyrazinamidase also is strongly correlated with virulence, and is part of the Wauters biotype schema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/3\">",
"     3",
"    </a>",
"    ]. Use of Congo Red-magnesium oxalate agar (CR-MOX) facilitates detection of the virulence plasmid capable of binding Congo Red dye, and calcium dependent growth at 37 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/11\">",
"     11",
"    </a>",
"    ]. PCR assays for the presence of specific chromosomal and plasmid-associated virulence determinants have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic assays have been described and used in some epidemiologic studies, but are of limited clinical utility due to crossreactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102678539\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogenic Y. enterocolitica pass through the stomach, adhere to gut epithelial cells, invade the gut wall, localize in lymphoid tissue within the gut wall and in regional mesenteric lymph nodes, and evade the host&rsquo;s cell mediated immune response. A 70 kilodalton virulence plasmid known as pYV has been associated with pathogenic Y. enterocolitica. Variants of this plasmid are also present in Y. pseudotuberculosis and Y. pestis, and the presence of the plasmid is closely correlated with calcium-dependency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/14\">",
"     14",
"    </a>",
"    ]. The organism&rsquo;s capacity to produce urease releases ammonia from urea, which buffers local gastric acidity and provides relative acid resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/15\">",
"     15",
"    </a>",
"    ]. Adherence and invasion of the mucosal cells occurs via invasin and other surface proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organism elaborates additional proteins that allow it to evade host defense mechanisms, including phagocytosis and the bactericidal action of serum. Two such proteins, Ail (attachment invasion locus) and YadA, are adhesins that also confer resistance to complement-mediated opsonization. The most complex of these additional proteins are the Yersinia outer membrane proteins (Yops), which are encoded by a 70 kilodalton virulence plasmid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/17\">",
"     17",
"    </a>",
"    ]. The presence of this plasmid is an important virulence determinant, although some pathogenic strains that lack the virulence plasmid have been described.",
"   </p>",
"   <p>",
"    The Yops are not simple outer membrane proteins, but an extraordinary array of effectors that are injected into host cells via a type III secretion system [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/18\">",
"     18",
"    </a>",
"    ]. The injector apparatus is assembled at 37 degrees, and injection occurs on contact with the target cell. The injected Yops rapidly paralyze phagocytes, block secretion of recruitment molecules such as TNF-alpha and IL-8, and appear to inhibit activation of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The cumulative effect is suppression of inflammation and evasion of phagocytosis.",
"   </p>",
"   <p>",
"    Some Y. enterocolitica strains have genes for an iron-binding siderophore known as yersiniabactin, which can efficiently bind iron in iron deprived sites, permitting continued rapid growth of Y. enterocolitica biotype 1B [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/20\">",
"     20",
"    </a>",
"    ]. Similar virulence mechanisms have been described in Y. pseudotuberculosis.",
"   </p>",
"   <p>",
"    The expression of many of these virulence characteristics is temperature dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/2\">",
"     2",
"    </a>",
"    ]. At 25&deg;C, the organism is motile and expresses urease and inv, while at 37&deg;C the organism is non-motile but other virulence factors are expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/21\">",
"     21",
"    </a>",
"    ]. This temperature dependence may be important for survival of the organism outside of the host and for pathogenesis in the host.",
"   </p>",
"   <p>",
"    A specific Yersinia heat-stable enterotoxin Yst has been described which is similar to the heat stable enterotoxin of enterotoxigenic E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Yst is secreted under temperature, pH, and osmolality conditions similar to that of the mammalian ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Y. enterocolitica biotype 1A has generally been regarded as avirulent, although some strains have been described that are clearly enteropathogenic even though they lack pYV and other known virulence determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/8,24\">",
"     8,24",
"    </a>",
"    ]. Therefore, it is likely that more virulence determinants remain to be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102678555\">",
"    <span class=\"h2\">",
"     Immunologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of reactive arthritis caused by Yersinia infection is likely to be related to an immune response to Yersinia antigens that cross-react with host antigens in susceptible individuals. The putative inciting Yersinia antigen has not been determined. Host tissue type appears to be the predominant co-factor; HLA-B27 is typically present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/25\">",
"     25",
"    </a>",
"    ]. T-cells derived from the joint fluid of patients with reactive arthritis have been reported to selectively kill HLA-B27&ndash;bearing cells that are also infected with Yersinia enterocolitica [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythema nodosum has also been reported in association with yersiniosis; it does not appear to be associated with HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22373/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3697367\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Y. enterocolitica and Y. pseudotuberculosis cause yersiniosis, a diarrheal illness. Members of the genus Yersinia are gram-negative coccobacilli; they are facultative anaerobes in the family Enterobacteriaceae. (See",
"      <a class=\"local\" href=\"#H102678491\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yersinia enterocolitica exhibits three noteworthy microbiological features. It is capable of multiplying at refrigerator temperatures (although its optimum growth temperature is 25 to 28&deg;C), many strains lack efficient intrinsic iron uptake mechanisms, and virulent strains require calcium-supplemented medium to grow at 37&deg;C. (See",
"      <a class=\"local\" href=\"#H102678527\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Yersinia grows well on MacConkey agar, but at routine incubation temperatures it forms small colorless lactose-negative colonies, which are easily overlooked unless plates are specifically examined for them. Selective growth medium is recommended in laboratories not familiar with the appearance of the colonies. The most widely studied is cefsulodin-irgasin-novobiocin (CIN) agar, which inhibits the growth of competing flora and produces a characteristic colony morphology (",
"      <a class=\"graphic graphic_figure graphicRef64722 \" href=\"UTD.htm?2/22/2405\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3697194\">",
"       'Laboratory isolation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathogenic Y. enterocolitica pass through the stomach, adhere to gut epithelial cells, invade the gut wall, localize in lymphoid tissue within the gut wall and in regional mesenteric lymph nodes, and evade the host&rsquo;s cell mediated immune response. (See",
"      <a class=\"local\" href=\"#H102678539\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Butler T. Plague and other Yersinia infections, Plenum Medical Books Co., New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/2\">",
"      Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev 1997; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/3\">",
"      Wauters G, Kandolo K, Janssens M. Revised biogrouping scheme of Yersinia enterocolitica. Contrib Microbiol Immunol 1987; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     Tsubokura M. Yersinioses other than plague. In: Laboratory Diagnosis of Infectious Diseases, Balows A, Hausler WJ Jr, Ohashi M, Turano A (Eds), Springer-Verlag, New York 1989. p.540.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/5\">",
"      Lobato MJ, Landeras E, Gonz&aacute;lez-Hevia MA, Mendoza MC. Genetic heterogeneity of clinical strains of Yersinia enterocolitica traced by ribotyping and relationships between ribotypes, serotypes, and biotypes. J Clin Microbiol 1998; 36:3297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/6\">",
"      Carniel E, Mazigh D, Mollaret HH. Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect Immun 1987; 55:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/7\">",
"      Cherchi GB, Cossellu S, Pacifico L, et al. Incidence and outcome of Yersinia enterocolitica infection in thalassemic patients. Contrib Microbiol Immunol 1995; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/8\">",
"      Burnens AP, Frey A, Nicolet J. Association between clinical presentation, biogroups and virulence attributes of Yersinia enterocolitica strains in human diarrhoeal disease. Epidemiol Infect 1996; 116:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/9\">",
"      Head CB, Whitty DA, Ratnam S. Comparative study of selective media for recovery of Yersinia enterocolitica. J Clin Microbiol 1982; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/10\">",
"      Farmer JJ 3rd, Carter GP, Miller VL, et al. Pyrazinamidase, CR-MOX agar, salicin fermentation-esculin hydrolysis, and D-xylose fermentation for identifying pathogenic serotypes of Yersinia enterocolitica. J Clin Microbiol 1992; 30:2589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/11\">",
"      Riley G, Toma S. Detection of pathogenic Yersinia enterocolitica by using congo red-magnesium oxalate agar medium. J Clin Microbiol 1989; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/12\">",
"      Feng P. Identification of invasive Yersinia species using oligonucleotide probes. Mol Cell Probes 1992; 6:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/13\">",
"      Bottone EJ, Sheehan DJ. Yersinia enterocolitica: guidelines for serologic diagnosis of human infections. Rev Infect Dis 1983; 5:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/14\">",
"      Cornelis GR, Boland A, Boyd AP, et al. The virulence plasmid of Yersinia, an antihost genome. Microbiol Mol Biol Rev 1998; 62:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/15\">",
"      De Koning-Ward TF, Robins-Browne RM. Contribution of urease to acid tolerance in Yersinia enterocolitica. Infect Immun 1995; 63:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/16\">",
"      Carniel E. Chromosomal virulence factors of Yersinia: an update. Contrib Microbiol Immunol 1995; 13:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/17\">",
"      Portnoy DA, Martinez RJ. Role of a plasmid in the pathogenicity of Yersinia species. Curr Top Microbiol Immunol 1985; 118:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/18\">",
"      Cornelis GR. Yersinia type III secretion: send in the effectors. J Cell Biol 2002; 158:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/19\">",
"      Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. Infect Immun 1998; 66:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/20\">",
"      Rakin A, Noelting C, Schubert S, Heesemann J. Common and specific characteristics of the high-pathogenicity island of Yersinia enterocolitica. Infect Immun 1999; 67:5265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/21\">",
"      Badger JL, Miller VL. Expression of invasin and motility are coordinately regulated in Yersinia enterocolitica. J Bacteriol 1998; 180:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/22\">",
"      Takao T, Tominaga N, Yoshimura S, et al. Isolation, primary structure and synthesis of heat-stable enterotoxin produced by Yersinia enterocolitica. Eur J Biochem 1985; 152:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/23\">",
"      Mikulskis AV, Delor I, Thi VH, Cornelis GR. Regulation of the Yersinia enterocolitica enterotoxin Yst gene. Influence of growth phase, temperature, osmolarity, pH and bacterial host factors. Mol Microbiol 1994; 14:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/24\">",
"      Morris JG Jr, Prado V, Ferreccio C, et al. Yersinia enterocolitica isolated from two cohorts of young children in Santiago, Chile: incidence of and lack of correlation between illness and proposed virulence factors. J Clin Microbiol 1991; 29:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/25\">",
"      Aho K, Ahvonen P, Lassus A, et al. HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease. Arthritis Rheum 1974; 17:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/26\">",
"      Hermann E, Yu DT, Meyer zum B&uuml;schenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993; 342:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22373/abstract/27\">",
"      Laitinen O, Leirisalo M, Skylv G. Relation between HLA-B27 and clinical features in patients with yersinia arthritis. Arthritis Rheum 1977; 20:1121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3134 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22373=[""].join("\n");
var outline_f21_54_22373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3697367\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102678491\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102678527\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3697194\">",
"      Laboratory isolation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102678539\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102678555\">",
"      Immunologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3697367\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3134|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/22/2405\" title=\"figure 1\">",
"      Appearance of Yersinia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=related_link\">",
"      Epidemiology of yersiniosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22374="Basiliximab: Drug information";
var content_f21_54_22374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Basiliximab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/61/10197?source=see_link\">",
"    see \"Basiliximab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=see_link\">",
"    see \"Basiliximab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Immunosuppressant Agent;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute renal transplant rejection prophylaxis:",
"     </b>",
"     I.V.: 20 mg within 2 hours prior to transplant surgery, followed by a second 20 mg dose 4 days after transplantation. The second dose should be withheld if complications occur (including severe hypersensitivity reactions or graft loss).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute cardiac transplant rejection prophylaxis (unlabeled use):",
"     </b>",
"     I.V.: 20 mg on the day of transplant, followed by a second dose 4 days after transplantation (Mehra, 2005); usually given within the first hour postoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute liver transplant rejection prophylaxis (unlabeled use):",
"     </b>",
"     I.V.: 20 mg within 6 hours of organ reperfusion, followed by a second 20 mg dose 4 days after transplantation (Neuhaus, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of refractory acute GVHD (unlabeled use):",
"     </b>",
"     I.V.: 20 mg on days 1 and 4; may repeat for recurrent acute GVHD (Schmidt-Hieber, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=see_link\">",
"      see \"Basiliximab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute renal transplant rejection prophylaxis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &lt;35 kg:",
"     </i>",
"     10 mg within 2 hours prior to transplant surgery, followed by a second 10 mg dose 4 days after transplantation; the second dose should be withheld if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;35 kg:",
"     </i>",
"     Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simulect&reg;: 10 mg [contains sucrose 10 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simulect&reg;: 20 mg [contains sucrose 20 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F139079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intravenous administration only. Infuse as a bolus or I.V. infusion over 20-30 minutes. (Bolus dosing is associated with nausea, vomiting, and local pain at the injection site.) Administer only after assurance that patient will receive renal graft and immunosuppression. For the treatment of acute GVHD (unlabeled use), the dose was diluted in 250 mL NS and administered over 30 minutes (Schmidt-Hieber, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of acute organ rejection in renal transplantation (in combination with cyclosporine and corticosteroids)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10084784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory acute graft-versus-host disease (GVHD); prevention of liver or cardiac transplant rejection",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of basiliximab did not appear to increase the incidence or severity of adverse effects in clinical trials. Adverse events were reported in 96% of both the placebo and basiliximab groups.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, wound complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hyper-/hypokalemia, hyperuricemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, infection (upper respiratory)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Abnormal heart sounds, angina, arrhythmia, atrial fibrillation, chest pain, generalized edema, heart failure, hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, depression, dizziness, fatigue, hypoesthesia, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cyst, hypertrichosis, pruritus, rash, skin disorder, skin ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, dehydration, diabetes mellitus, fluid overload, glucocorticoids increased, hyper-/hypocalcemia, hyperlipemia, hypertriglyceridemia, hypoglycemia, hypomagnesemia, hyponatremia, hypoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, esophagitis, flatulence, gastroenteritis, GI hemorrhage, gingival hyperplasia, melena, moniliasis, stomatitis (including ulcerative), weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Bladder disorder, dysuria, genital edema (male), impotence, ureteral disorder, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematoma, hemorrhage, leukopenia, polycythemia, purpura, thrombocytopenia, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, cramps, fracture, hernia, leg pain, myalgia, neuropathy, paresthesia, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, hematuria, nonprotein nitrogen increased, oliguria, renal function abnormal, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, bronchospasm, cough, pharyngitis, pneumonia, pulmonary edema, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental trauma, cytomegalovirus (CMV) infection, herpes infection (simplex and zoster), infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, capillary leak syndrome, cytokine release syndrome, diabetes (new onset), fasting glucose impaired, glucose intolerance, hypersensitivity reaction (including heart failure, hypotension, tachycardia, bronchospasm, dyspnea, pulmonary edema, respiratory failure, sneezing, pruritus, rash, urticaria), lymphoproliferative disease",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to basiliximab or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Severe hypersensitivity reactions, occurring within 24 hours, have been reported. Reactions, including anaphylaxis, have occurred both with the initial exposure and/or following re-exposure after several months; use caution during re-exposure to a subsequent course of therapy in a patient who has previously received basiliximab. Patients in whom concomitant immunosuppression was prematurely discontinued due to abandoned transplantation or early graft loss are at increased risk for developing a severe hypersensitivity reaction upon re-exposure. Discontinue permanently if a severe reaction occurs. Medications for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: In renal transplant patients receiving basiliximab plus prednisone, cyclosporine, and mycophenolate, new-onset diabetes, glucose intolerance, and impaired fasting glucose were observed at rates significantly higher than observed in patients receiving prednisone, cyclosporine, and mycophenolate without basiliximab (Aasebo, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human antimurine antibodies (HAMA): Treatment may result in the development of HAMA; however, limited evidence suggesting the use of muromonab-CD3 or other murine products is not precluded.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lymphoproliferative disorders: The incidence of lymphoproliferative disorders may be increased by immunosuppressive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opportunistic infections: The incidence of opportunistic infections may be increased by immunosuppressive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: To be used as a component of an immunosuppressive regimen which includes cyclosporine and corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppression therapy and organ transplant management.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3014510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: Echinacea may diminish the therapeutic effect of basiliximab. Avoid hypoglycemic herbs, including alfalfa, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng, gymnema, marshmallow, and stinging nettle (may enhance the hypoglycemic effect of basiliximab).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. IL-2 receptors play an important role in the development of the immune system. Use in pregnant women only when benefit exceeds potential risk to the fetus. Women of childbearing potential should use effective contraceptive measures before beginning treatment and for 4 months after completion of therapy with this agent. The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F139108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F139084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether basiliximab is excreted in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Simulect Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $2242.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $2942.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F139075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of acute rejection; hypersensitivity, infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, RU, SE, SG, SK, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Mean: 36 days (determined by IL-2R alpha saturation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Mean: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children 1-11 years: 4.8 &plusmn; 2.1 L; Adolescents 12-16 years: 7.8 &plusmn; 5.1 L; Adults: 8.6 &plusmn; 4.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children 1-11 years: 9.5 days; Adolescents 12-16 years: 9.1 days; Adults: Mean: 7.2 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aaseb&oslash; W, Midtvedt K, Valderhaug TG, et al, &ldquo;Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(4):1289-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/19934089/pubmed\" id=\"19934089\" target=\"_blank\">",
"        19934089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brennen DC, Daller JA, Lake KD, et al, &ldquo;Rabbit Antithymocyte Globulin Versus Basiliximab in Renal Transplantation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(19):1967-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/17093248/pubmed\" id=\"17093248\" target=\"_blank\">",
"        17093248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahan BD, Rajagopalan PR, and Hall M, &ldquo;Reduction of the Occurrence of Acute Cellular Rejection Among Renal Allograft Recipients Treated With Basiliximab, a Chimeric Anti-Interleukin-2-Receptor Monoclonal Antibody. United States Simulect Renal Study Group,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1999, 67(2):276-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/10075594/pubmed\" id=\"10075594\" target=\"_blank\">",
"        10075594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehra MR, Zucker MJ, Wagoner L, et al, &ldquo;A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation,&rdquo;",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2005, 24(9):1297-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/16143248/pubmed\" id=\"16143248\" target=\"_blank\">",
"        16143248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nashan B, Moore R, Amlot P, et al, &ldquo;Randomised Trial of Basiliximab Versus Placebo for Control of Acute Cellular Rejection in Renal Allograft Recipients,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 350(9086):1193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/9652559/pubmed\" id=\"9652559\" target=\"_blank\">",
"        9652559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neuhaus P, Clavien PA, Kittur D, et al, &ldquo;Improved Treatment Response With Basiliximab Immunoprophylaxis After Transplantation: Results From a Double-Blind Randomized Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Liver Transpl",
"      </i>",
"      , 2002, 8(2):132-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/11862589/pubmed\" id=\"11862589\" target=\"_blank\">",
"        11862589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Offner G, Toenshoff B, H&ouml;cker B, et al, &ldquo;Efficacy and Safety of Basiliximab in Pediatric Renal Transplant Patients Receiving Cyclosporine, Mycophenolate Mofetil, and Steroids,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2008, 86(9):1241-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/19005406/pubmed\" id=\"19005406\" target=\"_blank\">",
"        19005406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt-Hieber M, Feitz T, Knauf W, et al, &ldquo;Efficacy if the Interleukin-2 Receptor Antagonist Basiliximab in Steroid-Refractory Acute Graft-Versus-Host Disease,",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 130(4):568-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22374/abstract-text/16098072/pubmed\" id=\"16098072\" target=\"_blank\">",
"        16098072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8803 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22374=[""].join("\n");
var outline_f21_54_22374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708643\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139095\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139096\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139126\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139100\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139116\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139101\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673269\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673270\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139077\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139062\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139079\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139078\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10084784\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139124\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139082\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139066\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298813\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139071\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3014510\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139073\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139083\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139108\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139084\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323008\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139075\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139085\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139065\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139081\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/61/10197?source=related_link\">",
"      Basiliximab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=related_link\">",
"      Basiliximab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22375="Disorders of Bartholin gland";
var content_f21_54_22375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disorders of Bartholin gland",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Katherine T Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22375/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/54/22375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bartholin glands (also called the greater vestibular glands) are the female homologue of the bulbourethral glands in the male. Each gland is approximately 0.5 cm in size and drains tiny drops of mucus into a duct 2.5 cm long. The ducts open onto the vestibule at the four and eight o'clock positions on each side of the vaginal orifice, just below the hymenal ring (",
"    <a class=\"graphic graphic_figure graphicRef66162 \" href=\"UTD.htm?17/44/18126\">",
"     figure 1",
"    </a>",
"    ). A normal Bartholin gland is not palpable, except possibly in very thin women.",
"   </p>",
"   <p>",
"    Cysts and abscesses are the most common disorders of the Bartholin glands, occurring in 2 to 3 percent of women; carcinoma and benign tumors are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/1\">",
"     1",
"    </a>",
"    ]. However, many vaginal and vulvar lesions mimic Bartholin gland disorders and should be considered in the differential diagnosis of a vulvovaginal mass or abscess (",
"    <a class=\"graphic graphic_table graphicRef68201 \" href=\"UTD.htm?24/53/25435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    General principles of diagnosis and management of vulvar abscesses are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=see_link\">",
"     \"Vulvar abscess\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BARTHOLIN DUCT CYST",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the orifice of the Bartholin gland duct becomes obstructed, mucus produced by the gland accumulates, leading to cystic dilatation of the duct proximal to the obstruction. Obstruction is often caused by local or diffuse vulvar edema. Bartholin duct cysts are usually sterile and the gland is not affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartholin duct cysts average 1 to 3 cm in size and are usually unilateral and asymptomatic. Larger cysts may cause discomfort, typically during sexual intercourse, sitting, or ambulating.",
"   </p>",
"   <p>",
"    The diagnosis is clinical and based upon findings of a soft, painless mass in the area of the Bartholin gland (ie, medial labia majora or lower vestibular area). Most such cysts are detected during a routine pelvic examination or by the woman herself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No intervention is necessary for asymptomatic Bartholin cysts. A possible exception to this is women over age 40, for whom some experts suggest drainage and a biopsy be performed to exclude carcinoma. Biopsy is required for women of any age if there are findings suggestive of malignancy of the Bartholin gland or other vulvar site (eg, solid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fixed mass, skin lesions suggestive of malignancy) (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Carcinoma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link&amp;anchor=H3#H3\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\", section on 'Clinical manifestations'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Cysts that are disfiguring or symptomatic can be treated by the techniques described below (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Procedures for drainage and excision'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BARTHOLIN DUCT ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An obstructed Bartholin duct can become infected and form an abscess (",
"    <a class=\"graphic graphic_picture graphicRef79478 \" href=\"UTD.htm?14/32/14850\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures of Bartholin abscesses usually show polymicrobial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Sexually transmitted infections used to be identified in as many as one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/4-7\">",
"     4-7",
"    </a>",
"    ], but this proportion has been declining [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/3\">",
"     3",
"    </a>",
"    ]. These relationships are illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microbiological examination of aspirates from 224 Bartholin abscesses yielded 307 positive aerobic cultures and 118 positive anaerobic cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/3\">",
"       3",
"      </a>",
"      ]. The predominant aerobic bacteria were Escherichia coli (78 isolates), Staphylococcus species (40 isolates) and Streptococcus species (32 isolates); the most common anaerobic bacteria were Bacteroides species (30 isolates). There were four positive isolates for N. gonorrhea and one positive isolate for C. trachomatis (5 patients with sexually transmitted infections among 219 patients with positive cultures, about 2 percent).",
"     </li>",
"     <li>",
"      An older study of 62 women with Bartholin abscesses undergoing marsupialization reported four N. gonorrhea and one C. trachomatis isolates [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/8\">",
"       8",
"      </a>",
"      ]. Bacteriological examination of the uterine cervix yielded another case of N. gonorrhea and four more of C. trachomatis (10 patients with sexually transmitted infections among 62 patients with positive cultures, about 16 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Bartholin abscess is based upon characteristic clinical findings. Women usually present with such severe pain and swelling that they are unable to walk, sit, or have sexual intercourse. On examination, the abscess appears as a warm, tender, soft or fluctuant mass in the lower medial labia majora or lower vestibular area, occasionally surrounded by erythema (cellulitis) and edema (lymphangitis). A large abscess, however, can expand into the upper labia. Where the abscess is very close to the surface, pus may break through the thin layer of skin and drain spontaneously.",
"   </p>",
"   <p>",
"    In the past, purulent material obtained from a spontaneously draining wound or from incision and drainage was not always sent for culture because drainage was usually curative and infection was polymicrobial. However, this practice has changed because community-associated methicillin-resistant S. aureus (MRSA) infections now account for many skin abscesses, including vulvar abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. We obtain cultures for aerobic bacteria, with consideration of specialized tests (nucleic acid amplification) for gonorrhea and chlamydia in patients at high risk of sexually transmitted diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate pain relief occurs upon drainage of pus. Women with abscesses that point and rupture spontaneously may only need analgesics or soaking of the genital area with warm compresses or with Sitz baths. An unruptured abscess should be drained (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Procedures for drainage and excision'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Placebo-controlled randomized trials in patients with uncomplicated skin abscesses have shown no benefit from antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], although trials specifically in women with Bartholin abscesses have not been performed. It appears reasonable to limit antibiotic treatment to women with known or suspected gonorrhea or chlamydia infection and to women at high risk of complicated infection (extensive surrounding cellulitis, immunosuppression, risk for MRSA, systemic signs of infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/14\">",
"     14",
"    </a>",
"    ]. Rare cases of necrotizing fasciitis and sepsis after abscess drainage have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women at risk for complicated infection can receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    (400 mg orally daily for one week) to cover streptococcus species and E. coli, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg orally four times per day for one week) to cover staphylococcal species (including community-associated MRSA) and Bacteroides species. Women with sexually transmitted infection should be treated, as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link&amp;anchor=H22#H22\">",
"     \"Genital Chlamydia trachomatis infections in women\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=see_link\">",
"     \"Treatment of uncomplicated gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURES FOR DRAINAGE AND EXCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most procedures to treat Bartholin gland cysts or abscesses can be performed under local anesthesia and can be performed in an office or emergency room setting. However, more extensive incisions or excision of the gland typically require sedation or general anesthesia.",
"   </p>",
"   <p>",
"    There are no large comparative clinical trials that provide data for guiding therapeutic decisions. In general [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Incision and drainage is the simplest procedure and has minimal risk of complications, but it carries a high risk of recurrent",
"      <span class=\"nowrap\">",
"       cyst/abscess",
"      </span>",
"      formation.",
"     </li>",
"     <li>",
"      Word catheter placement and marsupialization are similarly effective and have a low risk of complications and a relatively low risk of cyst recurrence (less than 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/17\">",
"       17",
"      </a>",
"      ]. The marsupialization procedure is somewhat more complicated than Word catheter placement, but patients have less postprocedure discomfort.",
"     </li>",
"     <li>",
"      Drainage followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      stick ablation is simple and possibly more effective than either catheter placement or marsupialization, although data are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/17\">",
"       17",
"      </a>",
"      ]. Postprocedure discomfort is the major disadvantage.",
"     </li>",
"     <li>",
"      Laser therapy also may be more effective than catheter placement or marsupialization (recurrence rate 4 percent versus up to 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/17\">",
"       17",
"      </a>",
"      ]), but requires specialized training in use of laser equipment and incurs higher cost.",
"     </li>",
"     <li>",
"      Excision is a definitive treatment, but must be performed in an operating room and can be associated with significant hemorrhage and postprocedure morbidity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is generally recommended that women over age 40 with a Bartholin cyst or abscess undergo biopsy of the gland to exclude the possibility of an underlying carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision and drainage is a well-known, simple procedure that provides immediate relief of pressure. The",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    is lanced at or behind the hymenal ring to prevent vulvar scarring. We do not recommend this procedure alone since there is a high tendency for",
"    <span class=\"nowrap\">",
"     cysts/abscesses",
"    </span>",
"    to recur because outflow becomes obstructed again when the incised tissue edges reapproximate. There is no evidence that packing the cavity for a few hours or days promotes better wound healing or prevents recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5865?source=see_link\">",
"     \"Technique of incision and drainage for skin abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Word catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preference for initial treatment of a Bartholin duct",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    is incision and drainage supplemented by placement of a Word catheter (",
"    <a class=\"graphic graphic_picture graphicRef65445 \" href=\"UTD.htm?16/46/17134\">",
"     picture 2",
"    </a>",
"    ). The procedure can be performed under local anesthesia in the office or emergency department. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28659?source=see_link\">",
"     \"Word catheter placement for treatment of Bartholin cysts and abscesses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Word catheter is a balloon-tipped device that is inserted into the",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    cavity immediately after incision and drainage (",
"    <a class=\"graphic graphic_figure graphicRef59709 \" href=\"UTD.htm?7/27/7600\">",
"     figure 2",
"    </a>",
"    ). The bulb of the catheter is then inflated and left in place for at least four weeks to promote formation of an epithelialized tract for drainage of glandular secretions. The end of the catheter is tucked into the vagina to minimize discomfort. When the tract appears well epithelialized, the balloon is deflated and the catheter is removed in the office; anesthesia is not necessary.",
"   </p>",
"   <p>",
"    Recurrence rates of only 3 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main disadvantages of this approach are that the catheter may be irritating and often dislodges or falls out before the tract is epithelialized, thus placing the patient at increased risk of recurrence.",
"   </p>",
"   <p>",
"    Modifications of the Word catheter principle, such as use of a Jacobi ring catheter, have been proposed, but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Marsupialization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marsupialization refers to a procedure whereby a new ductal orifice is created by excising a 1 to 2 cm ellipse of tissue that includes the epithelial surface and the roof of the cyst. The incision is made where the cyst protrudes into the vestibule and just outside of the hymenal ring. The edge of the proximal duct wall is then grasped with fine forceps and everted onto the epithelial surface where it is sutured with interrupted absorbable sutures, thus creating a fenestration for egress of glandular secretions. The",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    cavity is irrigated; some clinicians insert a drain or pack for a few days, but this is probably unnecessary.",
"   </p>",
"   <p>",
"    Marsupialization can often be performed with local anesthesia or pudendal block in an office setting (",
"    <a class=\"graphic graphic_figure graphicRef60294 \" href=\"UTD.htm?5/58/6051\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/22\">",
"     22",
"    </a>",
"    ]. Nevertheless, the procedure takes longer and is more invasive than placement of a Word catheter; for this reason, we generally reserve this method for patients who have failed one or two placements of a Word catheter.",
"   </p>",
"   <p>",
"    Potential postoperative issues include hematoma formation, pain, infection, scarring, and dyspareunia. Recurrence rates of 5 to 20 percent have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Silver nitrate ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For this procedure, incision and drainage is performed and then a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    stick 0.5 cm in length and diameter is placed deep within the",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    cavity and the wound is covered with a gauze dressing. The patient is asked to return to the office in 48 hours, at which time the incision site is cleansed and necrotic tissue with the remaining silver nitrate particles is removed. Side effects include pain, chemical burns of nearby tissue, labial edema, ecchymoses, several days of discharge, and scarring.",
"   </p>",
"   <p>",
"    Data on the outcome of this procedure are promising, but limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial including 50 patients with Bartholin cysts or abscesses found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      ablation and complete excision were similarly effective: no patient developed a recurrence during two years follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/23\">",
"       23",
"      </a>",
"      ]. Operating and healing time were significantly shorter in the silver nitrate group.",
"     </li>",
"     <li>",
"      An observational study consisted of 52 patients with either a Bartholin cyst or abscess treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      ablation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/24\">",
"       24",
"      </a>",
"      ]. All of the patients had complete healing within 15 days, but two women had recurrences within the first two months. One of these patients was subsequently treated by excision and the other by repeat silver nitrate ablation, with no recurrences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    ablation with more traditional and less invasive procedures than excision has not been performed. Studies that compare silver nitrate ablation with incision and",
"    <span class=\"nowrap\">",
"     drainage/Word",
"    </span>",
"    catheter insertion or with marsupialization will help in deciding the role of this procedure in treatment of Bartholin cyst or abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carbon dioxide laser vaporization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser vaporization is an effective approach, but laser equipment and expertise in laser surgery are not widely available, and the equipment is expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. The procedure can be performed under local anesthesia in an appropriately equipped office. Bleeding and scar formation are minimal.",
"   </p>",
"   <p>",
"    In the largest study, a consecutive series of 200 patients with monolateral or bilateral Bartholin cysts underwent a standardized technique of cyst vaporization by carbon-dioxide laser in an outpatient setting under local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/25\">",
"     25",
"    </a>",
"    ]. The cyst mean size was 6.3",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    2.3 cm. The median operative time was 17 minutes (range 7 to 45 minutes); three cases were complicated by major intraoperative bleeding. A single laser treatment was curative in 95.7 percent of patients; nine patients had recurrent disease that was cured with one or two additional treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excision of the entire Bartholin gland and duct is the definitive procedure for treatment of both cysts and abscesses. It is usually only considered after other less invasive methods have repetitively failed or to exclude carcinoma in a woman over age 40 (although biopsy is preferred to complete excision). In contrast to other methods, excision carries a high risk of complications, particularly excessive bleeding. Other complications include hematoma formation, cellulitis, scarring, disfigurement, and dyspareunia. Loss of Bartholin gland function rarely causes vaginal dryness or dyspareunia.",
"   </p>",
"   <p>",
"    Excision must be performed in an operating room. Attention to hemostasis, recognition of inadvertent entry into the vagina or rectum, and ascertaining that the entire gland has been resected are important considerations during the procedure. The procedure is shown in the video (",
"    <a class=\"graphic graphic_movie graphicRef74807 \" href=\"UTD.htm?14/44/15054\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary carcinoma of the Bartholin gland is rare, accounting for fewer than 5 percent of all vulvar malignancies. Most cancers arising from the Bartholin gland and duct are adenocarcinomas or squamous cell carcinomas; adenoid cystic carcinoma, transitional cell carcinomas, and adenosquamous carcinoma make up the remainder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of Bartholin gland carcinoma is highest among women in their 60s. Most affected women do not have a past history of benign Bartholin gland disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of Bartholin gland cancer is as a painless vulvar mass. The mass may be solid, cystic, or abscessed, or a solid area may be palpated within a Bartholin duct cyst. Fixation to underlying tissue is suspicious for malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Bartholin gland carcinoma is based upon histological examination. It is generally recommended that women over age 40 with a Bartholin cyst or abscess undergo drainage and biopsy of the gland to exclude the possibility of an underlying carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy rather than excision is recommended because biopsy is a far less morbid procedure and the incidence of Bartholin gland cancer is exceedingly rare. This was best illustrated by data from a study involving a large hospital-based regional tumor registry and medical records from a tertiary hospital over a 24-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/18\">",
"     18",
"    </a>",
"    ]. In this series, the incidence of Bartholin gland carcinoma was 0.023 per 100,000 woman-years in premenopausal women and 0.114 per 100,000 woman-years in postmenopausal women. Of 13 postmenopausal women (mean age 65.4 years) with Bartholin gland enlargement admitted to the tertiary care center, 4 had excisions and the remainder had drainage or marsupialization. None of the patients treated with drainage or marsupialization were listed subsequently in the tumor registry as developing Bartholin gland cancer during a median surveillance of 10.3 years (range 1.7 to 14.4). Based on these data, the authors advocated a drainage procedure and biopsy as the initial evaluation of postmenopausal women with Bartholin gland enlargement.",
"   </p>",
"   <p>",
"    In our practice, we drain and biopsy the first Bartholin",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    in women over age 40 and recommend complete excision for recurrent disease. At a minimum, repeat biopsy should be performed in this population if a palpable mass persists after drainage of a",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    or the",
"    <span class=\"nowrap\">",
"     cyst/abscess",
"    </span>",
"    recurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic disease is common in cancers of Bartholin gland because of the rich vascular and lymphatic network of the vulva. Nevertheless, a study summarizing 30 years' clinical experience and involving 36 patients with Bartholin carcinoma reported a five-year survival rate of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Bartholin gland carcinoma should be referred to a gynecologic oncologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"     \"Vulvar cancer: Staging, treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BENIGN TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign solid tumors of Bartholin gland are even rarer than carcinoma, with only six cases reported in the English language literature since 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22375/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF A VULVOVAGINAL MASS OR ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, many vaginal and vulvar lesions mimic Bartholin gland disorders and should be considered in the differential diagnosis of a vulvovaginal mass or abscess (",
"    <a class=\"graphic graphic_table graphicRef68201 \" href=\"UTD.htm?24/53/25435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=see_link\">",
"       \"Patient information: Bartholin&rsquo;s gland cyst (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Bartholin glands are located bilaterally in the vestibule at approximately the four and eight o'clock positions with respect to the vaginal orifice (",
"      <a class=\"graphic graphic_figure graphicRef66162 \" href=\"UTD.htm?17/44/18126\">",
"       figure 1",
"      </a>",
"      ). Cysts and abscesses are the most common disorders of the Bartholin glands, occurring in 2 percent of women; carcinoma and benign tumors are rare. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bartholin duct cysts are usually asymptomatic or mildly bothersome, whereas abscesses are very tender and may be fluctuant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No intervention is necessary for asymptomatic Bartholin cysts, except in women over age 40 in whom drainage and biopsy should be performed to exclude a carcinoma. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Procedures for drainage and excision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with symptomatic cysts and abscesses, we suggest incision and drainage supplemented by placement of a Word catheter as the initial approach to treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Word catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who have recurrence of a cyst or abscess after one or two Word catheter placements, we suggest marsupialization as the second-line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Marsupialization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excision is the definitive therapy of cysts and abscesses, but it is associated with a high risk of hemorrhage and postoperative morbidity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presentation of Bartholin gland cancer is as a painless vulvar mass. The mass may be solid, cystic, or abscessed, or a solid area may be palpated within a Bartholin duct cyst. Fixation to underlying tissue is suspicious for malignancy. Women over age 40 with a Bartholin cyst or abscess should undergo drainage and biopsy of the gland to exclude the possibility of an underlying carcinoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/1\">",
"      Berger MB, Betschart C, Khandwala N, et al. Incidental bartholin gland cysts identified on pelvic magnetic resonance imaging. Obstet Gynecol 2012; 120:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/2\">",
"      Brook I. Aerobic and anaerobic microbiology of Bartholin's abscess. Surg Gynecol Obstet 1989; 169:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/3\">",
"      Tanaka K, Mikamo H, Ninomiya M, et al. Microbiology of Bartholin's gland abscess in Japan. J Clin Microbiol 2005; 43:4258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/4\">",
"      Aghajanian A, Bernstein L, Grimes DA. Bartholin's duct abscess and cyst: a case-control study. South Med J 1994; 87:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/5\">",
"      Lee YH, Rankin JS, Alpert S, et al. Microbiological investigation of Bartholin's gland abscesses and cysts. Am J Obstet Gynecol 1977; 129:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/6\">",
"      Rees E. Gonococcal bartholinitis. Br J Vener Dis 1967; 43:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/7\">",
"      Wren MW. Bacteriological findings in cultures of clinical material from Bartholin's abscess. J Clin Pathol 1977; 30:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/8\">",
"      Bleker OP, Smalbraak DJ, Schutte MF. Bartholin's abscess: the role of Chlamydia trachomatis. Genitourin Med 1990; 66:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/9\">",
"      Thurman AR, Satterfield TM, Soper DE. Methicillin-resistant Staphylococcus aureus as a common cause of vulvar abscesses. Obstet Gynecol 2008; 112:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/10\">",
"      Sherer DM, Dalloul M, Salameh G, Abulafia O. Methicillin-resistant Staphylococcus aureus bacteremia and chorioamnionitis after recurrent marsupialization of a bartholin abscess. Obstet Gynecol 2009; 114:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/11\">",
"      Laibl VR, Sheffield JS, Roberts S, et al. Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy. Obstet Gynecol 2005; 106:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/12\">",
"      Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/13\">",
"      Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/14\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/15\">",
"      Kohagura K, Sesoko S, Tozawa M, et al. [A female case of Fournier's gangrene in a patient with lupus nephritis]. Nihon Jinzo Gakkai Shi 1998; 40:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/16\">",
"      Lopez-Zeno JA, Ross E, O'Grady JP. Septic shock complicating drainage of a Bartholin gland abscess. Obstet Gynecol 1990; 76:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/17\">",
"      Marzano DA, Haefner HK. The bartholin gland cyst: past, present, and future. J Low Genit Tract Dis 2004; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/18\">",
"      Visco AG, Del Priore G. Postmenopausal bartholin gland enlargement: a hospital-based cancer risk assessment. Obstet Gynecol 1996; 87:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/19\">",
"      Word B. Office treatment of cyst and abscess of Bartholin's gland duct. South Med J 1968; 61:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/20\">",
"      Haider Z, Condous G, Kirk E, et al. The simple outpatient management of Bartholin's abscess using the Word catheter: a preliminary study. Aust N Z J Obstet Gynaecol 2007; 47:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/21\">",
"      Gennis P, Li SF, Provataris J, et al. Jacobi ring catheter treatment of Bartholin's abscesses. Am J Emerg Med 2005; 23:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/22\">",
"      Downs MC, Randall HW Jr. The ambulatory surgical management of Bartholin duct cysts. J Emerg Med 1989; 7:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/23\">",
"      Mungan T, U��ur M, Yal&ccedil;in H, et al. Treatment of Bartholin's cyst and abscess: excision versus silver nitrate insertion. Eur J Obstet Gynecol Reprod Biol 1995; 63:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/24\">",
"      Y&uuml;ce K, Zeyneloglu HB, B&uuml;k&uuml;lmez O, Kisnisci HA. Outpatient management of Bartholin gland abscesses and cysts with silver nitrate. Aust N Z J Obstet Gynaecol 1994; 34:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/25\">",
"      Fambrini M, Penna C, Pieralli A, et al. Carbon-dioxide laser vaporization of the Bartholin gland cyst: a retrospective analysis on 200 cases. J Minim Invasive Gynecol 2008; 15:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/26\">",
"      de G&oacute;is Speck NM, Belfort PN, Mendes P, et al. Carbon dioxide laser treatment of Bartholin's gland cyst. Clin Exp Obstet Gynecol 2007; 34:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/27\">",
"      Lashgari M, Keene M. Excision of Bartholin duct cysts using the CO2 laser. Obstet Gynecol 1986; 67:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/28\">",
"      Benedetti Panici P, Manci N, Bellati F, et al. CO2 laser therapy of the Bartholin's gland cyst: surgical data and functional short- and long-term results. J Minim Invasive Gynecol 2007; 14:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/29\">",
"      Davis GD. Management of Bartholin duct cysts with the carbon dioxide laser. Obstet Gynecol 1985; 65:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/30\">",
"      Copeland LJ, Sneige N, Gershenson DM, et al. Bartholin gland carcinoma. Obstet Gynecol 1986; 67:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22375/abstract/31\">",
"      Argenta PA, Bell K, Reynolds C, Weinstein R. Bartholin's gland hyperplasia in a postmenopausal woman. Obstet Gynecol 1997; 90:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5492 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-CAE3B5A741-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22375=[""].join("\n");
var outline_f21_54_22375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BARTHOLIN DUCT CYST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BARTHOLIN DUCT ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURES FOR DRAINAGE AND EXCISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Word catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Marsupialization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Silver nitrate ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carbon dioxide laser vaporization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BENIGN TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DIFFERENTIAL DIAGNOSIS OF A VULVOVAGINAL MASS OR ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5492|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/44/18126\" title=\"figure 1\">",
"      Location Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/27/7600\" title=\"figure 2\">",
"      Placement of word catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/58/6051\" title=\"figure 3\">",
"      Marsupialization Bartholin cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5492|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/32/14850\" title=\"picture 1\">",
"      Bartholin gland abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/46/17134\" title=\"picture 2\">",
"      Word catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5492|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?14/44/15054\" title=\"movie 1\">",
"      Bartholin gland excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/53/25435\" title=\"table 1\">",
"      Diagnosis of vulvovaginal mass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/2/12322?source=related_link\">",
"      Patient information: Bartholin&rsquo;s gland cyst (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5865?source=related_link\">",
"      Technique of incision and drainage for skin abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/3/19514?source=related_link\">",
"      Treatment of uncomplicated gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31464?source=related_link\">",
"      Vulvar abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28659?source=related_link\">",
"      Word catheter placement for treatment of Bartholin cysts and abscesses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22376="Melphalan: Drug information";
var content_f21_54_22376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Melphalan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/26/17830?source=see_link\">",
"    see \"Melphalan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=see_link\">",
"    see \"Melphalan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alkeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alkeran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Details regarding dosing in combination regimens should also be consulted. Adjust dose based on patient response and weekly blood counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (palliative treatment):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Response is gradual; may require repeated courses to realize benefit:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Usual dose (as described in the manufacturer&rsquo;s labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6 mg once daily for 2-3 weeks initially, followed by up to 4 weeks rest, then a maintenance dose of 2 mg daily as hematologic recovery begins",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mg daily for 7-10 days; institute 2 mg daily maintenance dose after WBC &gt;4000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     (~4-8 weeks); titrate maintenance dose to hematologic response",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.15 mg/kg/day for 7 days, with a 2-6 week rest, followed by a maintenance dose of &le;0.05 mg/kg/day as hematologic recovery begins",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.25 mg/kg/day for 4 days (or 0.2 mg/kg/day for 5 days); repeat at 4- to 6-week intervals as ANC and platelet counts return to normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Other dosing regimens in",
"      <b>",
"       combination therapy",
"      </b>",
"      (unlabeled doses):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days every 4 weeks (in combination with prednisone",
"     <b>",
"      or",
"     </b>",
"     with prednisone and thalidomide) (Palumbo, 2006; Palumbo, 2008)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days every 4 weeks (in combination with prednisone) (Palumbo, 2004)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     0.25 mg/kg/day for 4 days every 6 weeks (in combination with prednisone [Facon, 2006; Facon, 2007]",
"     <b>",
"      or",
"     </b>",
"     with prednisone and thalidomide [Facon, 2007])",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every 6 weeks (in combination with prednisone",
"     <b>",
"      or",
"     </b>",
"     with prednisone and bortezomib) (Dimopoulos, 2009; San Miguel, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 16 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     administered at 2-week intervals for 4 doses, then  administer at 4-week intervals after adequate hematologic recovery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian carcinoma:",
"     </b>",
"     Oral: 0.2 mg/kg/day for 5 days, repeat every 4-5 weeks",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unlabeled dosing: 7 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 divided doses for 5 days, repeat every 28 days (Wadler, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amyloidosis, light chain (unlabeled use):",
"     </b>",
"     Oral: 0.22 mg/kg/day for 4 days every 28 days (in combination with oral dexamethasone) (Palladini, 2004)",
"     <b>",
"      or",
"     </b>",
"     10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every month (in combination with oral dexamethasone) for 12-18 treatment cycles (Jaccard, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 6 of combination chemotherapy (mini-BEAM) regimen (Colwill, 1995; Martin, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conditioning regimen for autologous hematopoietic stem cell transplantation (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     alone 2 days prior to transplantation (Fermand, 2005; Moreau, 2002)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     2 days prior to transplantation (combined with busulfan) (Fermand, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     2 days prior to transplantation (combined with total body irradiation [TBI]) (Moreau, 2002)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     5 days prior to transplantation (combined with TBI) (Barlogie, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F192411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=see_link\">",
"      see \"Melphalan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details regarding dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conditioning regimen for autologous hematopoietic stem cell transplantation (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     2 days prior to transplantation (combined with busulfan) (Canete, 2009; Oberlin, 2006)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (with pre- and posthydration) 12-30 hours prior to transplantation (Pritchard, 2005)",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days starting 8 days prior to transplantation (combined with busulfan or etoposide and carboplatin) (Berthold, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use caution and begin at the lower end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F192389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The FDA-approved labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Moderate-to-severe renal impairment: Consider a reduced dose initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: BUN &ge;30 mg/dL: Reduce dose by up to 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      The following guidelines have been used by some clinicians:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aronoff, 2007 (route of administration not specified): Adults (based on a 6 mg once-daily dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 75% of  dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Administer dose after hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous ambulatory peritoneal dialysis (CAPD): Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Carlson, 2005: Oral (for melphalan-prednisone combination therapy; based on a study evaluating toxicity with melphalan dosed at 0.25 mg/kg/day for 4 days/cycle):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 to &lt;30 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;10 mL/minute: Data is insufficient for a recommendation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kintzel, 1995:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Adjust dose in the presence of hematologic toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     46-60 mL/minute: Administer 85% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-45 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Administer 70% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Badros, 2001: I.V.: Autologous stem cell transplant (single-agent conditioning regimen; no busulfan or irradiation): Serum creatinine &gt;2 mg/dL: Reduce dose from 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 2 days (as 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days) to 140 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     given as  a single-dose infusion",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5528483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Melphalan is hepatically metabolized; however, dosage adjustment does not appear to be necessary (King, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F10146784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     WBC &lt;3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment until recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment until recovery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.V.: Adjust dose based on nadir blood cell counts",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alkeran&reg;: 50 mg [contains ethanol (in diluent), propylene glycol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alkeran&reg;: 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer on an empty stomach (1 hour prior to or 2 hours after meals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Due to limited stability, complete administration of I.V. dose should occur within 60 minutes of reconstitution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Infuse over 15-30 minutes. Extravasation may cause local tissue damage; administration by slow injection into a fast running I.V. solution into an injection port or via a central line is recommended; do not administer by direct injection into a peripheral vein.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F192438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amikacin, aminophylline, ampicillin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, caspofungin, cefazolin, cefepime, cefotaxime, cefotetan, ceftazidime, cefuroxime, cimetidine, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, famotidine, filgrastim, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gentamicin, granisetron, haloperidol lactate, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, ifosfamide, imipenem/cilastatin, lorazepam, mannitol, mechlorethamine, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, mitomycin, mitoxantrone, morphine, nalbuphine, ondansetron, pentostatin, piperacillin, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, streptozocin, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, chlorpromazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of multiple myeloma and nonresectable epithelial ovarian carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3034718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin lymphoma, light chain amyloidosis; conditioning regimen for autologous hematopoietic stem cell transplantation in adults with hematologic disorders (eg, multiple myeloma) and autologous marrow or stem cell transplantation in pediatric neuroblastoma and Ewing&rsquo;s sarcoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Melphalan may be confused with Mephyton&reg;, Myleran&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alkeran&reg; may be confused with Alferon&reg;, Leukeran&reg;, Myleran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting, diarrhea, oral ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression, leukopenia (nadir: 14-21 days; recovery: 28-35 days), thrombocytopenia (nadir: 14-21 days; recovery: 28-35 days), anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Secondary malignancy (&lt;2% to 20%; cumulative dose and duration dependent, includes acute myeloid leukemia, myeloproliferative syndrome, carcinoma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Miscellaneous: Hypersensitivity (I.V.: 2%; includes bronchospasm, dyspnea, edema, hypotension, pruritus, rash, tachycardia, urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infrequent, frequency undefined, postmarketing, and/or case reports: Agranulocytosis, allergic reactions, alopecia, amenorrhea, anaphylaxis (rare), bleeding (with high-dose therapy),, bone marrow failure (irreversible), BUN increased, cardiac arrest, cardiotoxicity (angina, arrhythmia, hypertension, MI; with high-dose therapy), encephalopathy, hemolytic anemia, hemorrhagic cystitis, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease; high-dose I.V. melphalan), hepatitis, infection, injection site reactions (ulceration, necrosis), interstitial pneumonitis, jaundice, mucositis (with high-dose therapy), ovarian suppression, paralytic ileus (with high-dose therapy), pruritus, pulmonary fibrosis, radiation myelopathy, rash (maculopapular), renal toxicity (with high-dose therapy), seizure (with high-dose therapy), sepsis, SIADH, skin hypersensitivity, sterility, stomatitis, testicular suppression, tingling sensation, transaminases increased, vasculitis, warmth sensation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to melphalan or any component of the formulation; patients whose disease was resistant to prior melphalan therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Bone marrow suppression is common; may be severe and result in infection or bleeding; has been demonstrated more with the I.V. formulation (compared to oral).",
"     </b>",
"     Myelosuppression is dose-related. Monitor blood counts; may require treatment delay or dose modification for thrombocytopenia or neutropenia. Use with caution in patients with prior bone marrow suppression, impaired renal function (consider dose reduction), or who have received prior (or concurrent) chemotherapy or irradiation. Myelotoxicity is generally reversible, although irreversible bone marrow failure has been reported. In patients who are candidates for autologous transplantation, avoid melphalan-containing regimens prior to transplant (due to the effects on stem cell reserve).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fertility effects: Suppresses ovarian function and  produces amenorrhea; may also cause testicular suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity:  Gastrointestinal toxicities, including nausea, vomiting, diarrhea and mucositis are common. When administering high-dose melphalan in autologous transplantation, cryotherapy is recommended to prevent mucositis (Keefe, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Abnormal liver function tests may occur; hepatitis and jaundice have also been reported. Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) has been reported with I.V. melphalan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Hypersensitivity reactions (including anaphylaxis) have occurred in ~2% of patients receiving I.V. melphalan,",
"     </b>",
"     usually after multiple treatment cycles. Discontinue infusion and treat symptomatically. Hypersensitivity may also occur (rarely) with oral melphalan. Do not readminister (oral or I.V.) in patients who experience hypersensitivity to melphalan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Pulmonary fibrosis (some fatal) and interstitial pneumonitis have been observed with treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Produces chromosomal abnormalities and is leukemogenic and potentially mutagenic.",
"     </b>",
"     Secondary malignancies (including acute myeloid leukemia, myeloproliferative disease, and carcinoma) have been reported (some patients were receiving combination chemotherapy or radiation therapy); the risk is increased with increased treatment duration and cumulative doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Signs of infection, such as fever and WBC rise, may not occur; lethargy and confusion may be more prominent signs of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dosage reduction is recommended with I.V. melphalan in patients with renal impairment; reduced initial doses may also be recommended with oral melphalan. Closely monitor patients with azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Toxicity may be increased in elderly; start with lowest recommended adult doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage from specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravenous: Extravasation may cause local tissue damage. Administration by slow injection into a fast running I.V. solution into an injection port or via a central line is recommended; do not administer directly into a peripheral vein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Avoid vaccination with live vaccines during treatment if immunocompromised.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carmustine: Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Melphalan may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nalidixic Acid: May enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F192378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food interferes with oral absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3034719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated embryotoxicity and teratogenicity. Therapy may suppress ovarian function leading to amenorrhea. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid pregnancy while on melphalan therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13265279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, melphalan should not be administered if breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F192368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach (1 hour prior to or 2 hours after meals).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F192367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Alkeran Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $1971.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Melphalan HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $1922.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F192356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum electrolytes, serum uric acid",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alkeran (AE, AT, AU, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CY, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PH, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Alkerana (AR);",
"     </li>",
"     <li>",
"      Melfalan (ES);",
"     </li>",
"     <li>",
"      Melpha (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetics listed are for FDA-approved doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Variable and incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg; low penetration into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 53% to 92%; primarily to albumin (40% to 60%), ~20% to &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Variable; 56% to 93%; exposure is reduced with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: I.V.: 75 minutes; Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Oral: Feces (20% to 50%); urine (~10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alberts DS, Chang SY, Chen HS, et al, &ldquo;Oral Melphalan Kinetics,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(6):737-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/498715/pubmed\" id=\"498715\" target=\"_blank\">",
"        498715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Badros A, Barlogie B, Siegel E, et al, &ldquo;Results of Autologous Stem Cell Transplant in Multiple Myeloma Patients With Renal Failure,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 114(4):822-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/11564069/pubmed\" id=\"11564069\" target=\"_blank\">",
"        11564069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barlogie B, Kyle RA, Anderson KC, et al, &ldquo;Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(6):929-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16432076/pubmed\" id=\"16432076\" target=\"_blank\">",
"        16432076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berthold F, Boos J, Burdach S, et al, &ldquo;Myeloablative Megatherapy With Autologous Stem-Cell Rescue Versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients With High-Risk Neuroblastoma: A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2005, 6(9):649-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16129365/pubmed\" id=\"16129365\" target=\"_blank\">",
"        16129365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canete A, Gerrard M. Rubie H, et al, &ldquo;Poor Survival for Infants with MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society for Paediatric Oncology European Neuroblastoma Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(7):1014-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/19171715/pubmed\" id=\"19171715\" target=\"_blank\">",
"        19171715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carlson K, Hjorth M, Knudsen LM, et al, &ldquo;Toxicity in Standard Melphalan-Prednisone Therapy Among Myeloma Patients With Renal Failure - A Retrospective Analysis and Recommendations for Dose Adjustment,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 128(5):631-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/15725084/pubmed\" id=\"15725084\" target=\"_blank\">",
"        15725084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colwill R, Crump M, Couture F, et al, &ldquo;Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin&rsquo;s Disease Before Intensive Therapy or Autologous Bone Marrow Transplantation,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(2):396-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/7844600/pubmed\" id=\"7844600\" target=\"_blank\">",
"        7844600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dimopoulos MA, Richardson PG, Schlag R, et al, &ldquo;VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(36):6086-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/19858394/pubmed\" id=\"19858394\" target=\"_blank\">",
"        19858394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Facon T, Mary JY, Hulin C, et al, &ldquo;Melphalan and Prednisone Plus Thalidomide Versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients With Multiple Myeloma (IFM 99-06): A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9594):1209-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/17920916/pubmed\" id=\"17920916\" target=\"_blank\">",
"        17920916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Facon T, Mary JY, Pegourie B, et al, &ldquo;Dexamethasone-Based Regimens versus Melphalan-Prednisone for Elderly Multiple Myeloma Patients Ineligible for High-Dose Therapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(4):1292-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16174762/pubmed\" id=\"16174762\" target=\"_blank\">",
"        16174762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fermand JP, Katsahian S, Divine M, et al, &ldquo;High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(36):9227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16275936/pubmed\" id=\"16275936\" target=\"_blank\">",
"        16275936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaccard A, Moreau P, Leblond V, et al, &ldquo;High-Dose Melphalan versus Melphalan Plus Dexamethasone for AL Amyloidosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(11):1083-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/17855669/pubmed\" id=\"17855669\" target=\"_blank\">",
"        17855669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keefe DM, Schubert MM, Elting LS, et al, &ldquo;Updated Clinical Practice Guidelines for the Prevention and Treatment of Mucositis,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(5):820-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/17236223/pubmed\" id=\"17236223\" target=\"_blank\">",
"        17236223",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin A, Fernandez-Jimenez MC, Caballero MD, et al, &ldquo;Long-Term Follow-Up in Patients Treated with Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin&rsquo;s Disease,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2001, 113(1):161-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/11328296/pubmed\" id=\"11328296\" target=\"_blank\">",
"        11328296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreau P, Facon T, Attal M, et al, &ldquo;Comparison of 200 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      Melphalan and 8 Gy Total Body Irradiation Plus 140 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      Melphalan as Conditioning Regimens for Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of the Intergroupe Francophone du My&eacute;lome 9502 Randomized Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(3):731-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/11806971/pubmed\" id=\"11806971\" target=\"_blank\">",
"        11806971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nath CE, Shaw PJ, Montgomery K, et al, &ldquo;Population Pharmacokinetics of Melphalan in Pediatric Blood or Marrow Transplant Recipients,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(2):151-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/17324241/pubmed\" id=\"17324241\" target=\"_blank\">",
"        17324241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nath CE, Shaw PJ, Trotman J, et al, &ldquo;Population Pharmacokinetics of Melphalan in Patients With Multiple Myeloma Undergoing High Dose Therapy,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2010, 69(5):484-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/20573084/pubmed\" id=\"20573084\" target=\"_blank\">",
"        20573084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oberlin O, Rey A, Desfachelles AS, et al, &ldquo;Impact of High-Dose Busulfan Plus Melphalan as Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l&rsquo;Enfant,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(24):3997-4002.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16921053/pubmed\" id=\"16921053\" target=\"_blank\">",
"        16921053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palladini G, Perfetti V, Obici L, et al, &ldquo;Association of Melphalan and High-Dose Dexamethasone is Effective and Well Tolerated in Patients With AL (Primary) Amyloidosis Who are Ineligible for Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(8):2936-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/15070667/pubmed\" id=\"15070667\" target=\"_blank\">",
"        15070667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Caravita T, et al, &ldquo;Oral Melphalan and Prednisone Chemotherapy Plus Thalidomide Compared With Melphalan and Prednisone Alone in Elderly Patients With Multiple Myeloma: Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9513):825-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16530576/pubmed\" id=\"16530576\" target=\"_blank\">",
"        16530576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Liberati AM, et al, &ldquo;Oral Melphalan, Prednisone, and Thalidomide in Elderly Patients With Multiple Myeloma: Updated Results of a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(8):3107-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/18505783/pubmed\" id=\"18505783\" target=\"_blank\">",
"        18505783",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palumbo A, Bringhen S, Petrucci MT, et al, &ldquo;Intermediate-Dose Melphalan Improves Survival of Myeloma Patients Aged 50 to 70: Results of a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 104(10):3052-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/15265788/pubmed\" id=\"15265788\" target=\"_blank\">",
"        15265788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pinguet F, Martel P, Rouanet P, et al, &ldquo;Effect of Sodium Chloride Concentration and Temperature on Melphalan Stability During Storage and Use,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1994, 51(21):2701-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/7856585/pubmed\" id=\"7856585\" target=\"_blank\">",
"        7856585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritchard J, Cotterill SJ, Germond SM, et al, &ldquo;High Dose Melphalan in the Treatment of Advanced Neuroblastoma: Results of a Randomised Trial (ENSG-1) by the European Neuroblastoma Study Group,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2005, 44(4):348-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/15546135/pubmed\" id=\"15546135\" target=\"_blank\">",
"        15546135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2008, 359(9):906-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/18753647/pubmed\" id=\"18753647\" target=\"_blank\">",
"        18753647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuh A, Dandridge J, Haydon P, et al, &ldquo;Encephalopathy Complicating High-Dose Melphalan,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1999, 24(10):1141-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/10578165/pubmed\" id=\"10578165\" target=\"_blank\">",
"        10578165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seddon BM, Cassoni AM, Galloway MJ, et al, &ldquo;Fatal Radiation Myelopathy After High-Dose Busulfan and Melphalan Chemotherapy and Radiotherapy for Ewing&rsquo;s Sarcoma: A Review of the Literature and Implications for Practice,&rdquo;",
"      <i>",
"       Clin Oncol",
"      </i>",
"      , 2005, 17(5):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/16097572/pubmed\" id=\"16097572\" target=\"_blank\">",
"        16097572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wadler S, Yeap B, Vogl S, et al, &ldquo;Randomized Trial of Initial Therapy With Melphalan Versus Cisplatin-Based Combination Chemotherapy in Patients With Advanced Ovarian Carcinoma: Initial and Long Term Results -- Eastern Cooperative Oncology Group Study E2878,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1996, 77(40):733-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/54/22376/abstract-text/8616766/pubmed\" id=\"8616766\" target=\"_blank\">",
"        8616766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9605 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-EEAAC3DE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22376=[""].join("\n");
var outline_f21_54_22376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709032\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192432\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192387\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192411\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192388\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192389\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528483\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10146784\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192358\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192362\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192438\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192361\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034718\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192441\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192430\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192365\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192346\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299659\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192378\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192354\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034719\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192399\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265279\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192368\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192367\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192356\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192369\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192345\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192364\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/26/17830?source=related_link\">",
"      Melphalan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/41/43670?source=related_link\">",
"      Melphalan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22377="Clinical manifestations and pathogenesis of human parvovirus B19 infection";
var content_f21_54_22377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Jeanne A Jordan, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22377/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/54/22377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human parvovirus B19 (B19) belongs to the Erythrovirus genus within the Parvoviridae family [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/1\">",
"     1",
"    </a>",
"    ]. B19 was first discovered in 1975 while screening units of blood for hepatitis B virus in asymptomatic donors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/2\">",
"     2",
"    </a>",
"    ]. Sample 19 in panel B (hence the name parvovirus B19) was read as a false positive result on a counterimmunoelectrophoresis assay. B19 is the predominant parvovirus pathogen in humans, and as such, B19 is the prototype strain for genotype 1. The other less common and more recently described erythroviruses infecting humans include genotype 2 (prototype strain, LaLi) and genotype 3 (prototype strain, V9) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The nucleotide sequence differs among the three genotypes of B19 virus by 13 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Genotypes 1 and 2 are typically found in western countries (eg, USA and Europe), while genotype 3 is found primarily in sub-Saharan Africa and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/7\">",
"     7",
"    </a>",
"    ], but is spreading.",
"   </p>",
"   <p>",
"    Parvovirus B19 was first associated with clinical disease in 1981.",
"   </p>",
"   <p>",
"    Infection can lead to a variety of clinical manifestations dependent on the underlying host. In children, parvovirus B19 can cause erythema infectiosum (EI), a mild febrile illness with rash. In contrast, patients with underlying hemolytic disorders can develop transient aplastic crisis and infection during pregnancy can lead to fetal death.",
"   </p>",
"   <p>",
"    The pathogenesis and clinical manifestations of parvovirus infection will be discussed here. The epidemiology, transmission, diagnosis, and treatment of this infection, as well as the management of infection during pregnancy, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=see_link\">",
"     \"Parvovirus B19 infection during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 is a small (26 nm), non-enveloped, ssDNA (5.6-kb) virus. The capsid consists of a minor structural protein, VP1 and a major structural protein, VP2; these two proteins are encoded by overlapping reading frames. During permissive infection, these structural proteins and a non-structural protein, NS1, are produced. NS1 is a DNA binding protein with helicase, nicking, and ATPase activities. NS1 plays an important role in regulating DNA replication and inducing cellular apoptosis. The inflammatory response associated with B19 infection may be the result of NS1 transactivation of pro-inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only known host for B19 is humans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/9\">",
"     9",
"    </a>",
"    ]. The virus replicates in erythroid progenitor cells (late erythroid cell precursors and burst-forming erythroid progenitors) of the bone marrow and blood leading to inhibition of erythropoiesis, which can result in symptoms of anemia. To date, erythroid precursor cells of the colony and burst forming units (E-CFU and E-BFU) are the only cells known to support a fully productive infection with B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observed tropism of parvovirus is most likely due to the distribution of its cellular receptor, P blood group antigen, globoside, which is found in high concentrations on red blood cells and their precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/11\">",
"     11",
"    </a>",
"    ]. Rare individuals who lack P antigen are resistant to infection with parvovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Globoside is also found to a lesser extent on other cell types, including endothelial cells, cardiomyocytes, megakaryocytes, and placental trophoblast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The globoside-containing, non-erythroid cell types that become infected with B19 produce little if any infectious virus. However, these nonproductive infections may contribute to disease through the expression of nonstructural (NS1) protein, which can induce cellular apoptosis in both permissive and non-permissive cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/10,15-17\">",
"     10,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although parvovirus B19 infects cells expressing P antigen, some cell lines that are positive for P antigen fail to bind, whereas other cell lines have an ability to bind parvovirus B19 despite lack of P antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/18\">",
"     18",
"    </a>",
"    ]. One group of researchers has also not been able to confirm virus binding to membrane-associated globoside in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/19\">",
"     19",
"    </a>",
"    ]. A coreceptor has been identified that is necessary for virus entry into target cells, a process mediated by alpha 5 beta 1 integrins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/20\">",
"     20",
"    </a>",
"    ]. Ku80, an autoantigen, is also a candidate co-receptor for B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral DNA replication, RNA transcription, protein translation, and virus capsid assembly all occur in the cell's nucleus. Virus particles can be visualized in the nucleus by electron microscopy (EM).",
"   </p>",
"   <p>",
"    Upon viral maturation, B19 causes cell lysis. The cytopathic effect induced during B19 infection can be seen in the form of giant pronormoblasts located in the patient's bone marrow. These cells contain large eosinophilic nuclear inclusions, cytoplasmic vacuolization, and marginated chromatin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMUNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viremia occurs 7 to 10 days after exposure and usually lasts approximately five days, with virus titers peaking on the first few days of infection, which can reach or exceed 10(12) particles per milliliter of blood. Parvovirus B19-specific IgM antibodies are detected at day 10 through 12 and can persist for up to five months; specific IgG antibodies are detectable about 15 days post-infection and persist long-term. The close timing that exists between developing B19-specific IgM and IgG antibodies means that it is rare to find an IgM-positive serum sample that is not also IgG-positive. The role of the humoral immune system appears dominant; development of the antibody response corresponds to virus clearance and subsequent protection from disease. Antibodies to VP1 are required for an effective immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parvovirus B19 infection also elicits an inflammatory cell-mediated immune response, including the production of tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Evidence for a possible role of CD8 T cells in the control of parvovirus was suggested by one study that longitudinally analyzed the CD8 T cell responses in acutely infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/27\">",
"     27",
"    </a>",
"    ]. A striking CD8 T cell response was maintained and eventually increased over several months after the resolution of illness. The importance of cellular immunity is also suggested by clinical reports of remission of parvovirus induced anemia after initiation of highly active antiretroviral therapy in advanced AIDS patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ISSUES OF INFECTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period and infectivity of parvovirus is discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentations associated with B19 infection vary greatly, ranging from benign to life threatening. The clinical presentation is influenced by the infected individual's age and hematologic and immunologic status.",
"   </p>",
"   <p>",
"    Most immunocompetent people with detectable B19-specific IgG do not recall ever having any specific symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately 25 percent of infected individuals will be completely asymptomatic during their infection, while 50 percent will have only non-specific flu-like symptoms of malaise, muscle pain, and fever. The remaining 25 percent of infected individuals will present with the classic symptoms of B19 infection including rash, arthralgia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features in an otherwise normal, healthy individual were well depicted in a study performed in human volunteers who were inoculated intranasally with B19 virus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/32\">",
"     32",
"    </a>",
"    ]. The incubation period for this viral infection was 4 to 14 days. The infected volunteers had a typical biphasic illness (",
"    <a class=\"graphic graphic_figure graphicRef75004 \" href=\"UTD.htm?29/45/30430\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first week after inoculation, intense viremia was accompanied by a non-specific flu-like illness, with symptoms of fever, malaise, myalgia, coryza, headache, and pruritus. Hematologic abnormalities, including reticulocytopenia, reduced hemoglobin concentration, leukopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia were observed.",
"     </li>",
"     <li>",
"      In the following week, the more specific symptoms of rash",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arthralgia occurred. The rash in adults is less characteristic than the rash seen in children and may be confused with rubella. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Erythema infectiosum'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are five well-established syndromes associated with B19 infection:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fifth disease",
"     </li>",
"     <li>",
"      Arthropathy",
"     </li>",
"     <li>",
"      Non-immune hydrops fetalis, intrauterine fetal death, or miscarriage",
"     </li>",
"     <li>",
"      Transient aplastic crisis in those with chronic hemolytic disorders",
"     </li>",
"     <li>",
"      Chronic pure red blood cell aplasia in immunocompromised individuals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide range of other syndromes have been reported to be associated with B19 infections, but a causal role for the virus has yet to be conclusively established [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erythema infectiosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema infectiosum (EI) often occurs in outbreaks among school-aged children, although it can occur in adults as well [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/34\">",
"     34",
"    </a>",
"    ]. EI is also referred to as \"fifth disease\" since it represents one of six common childhood exanthems, each named in order of the dates they were first described.",
"   </p>",
"   <p>",
"    The illness begins with nonspecific prodromal symptoms, such as fever, coryza, headache, nausea, and diarrhea (",
"    <a class=\"graphic graphic_table graphicRef66085 \" href=\"UTD.htm?17/27/17851\">",
"     table 1",
"    </a>",
"    ). These constitutional symptoms coincide with onset of viremia. Two to five days later, the classic erythematous malar rash appears (the so-called slapped cheek rash) with relative circumoral pallor. This facial rash is often followed by a reticulated or lacelike rash on the trunk and extremities (",
"    <a class=\"graphic graphic_picture graphicRef71737 graphicRef75125 \" href=\"UTD.htm?9/61/10196\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The estimated incubation period from exposure to the onset of rash has usually been between one and two weeks but can be as long as three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/34\">",
"     34",
"    </a>",
"    ]. By the time the rash develops, viremia has resolved and the child usually feels well. The rash is thought to be immunologically mediated.",
"   </p>",
"   <p>",
"    A typical feature of EI is recrudescence of rash after a variety of nonspecific stimuli, such as change in temperature, exposure to sunlight, exercise, or emotional stress. In most patients, symptoms resolve within a few weeks, but symptoms can last for months, or rarely even years, in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B19 infection has also been associated with other types of rashes including morbilliform, confluent, and vesicular rashes. In the Gianotti-Crosti syndrome, a papulovesicular acrodermatitis may be accompanied by severe pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/37\">",
"     37",
"    </a>",
"    ]. Parvovirus B19 DNA was also identified by polymerase chain reaction in a cutaneous biopsy specimen of a patient with papular-purpuric \"gloves and socks\" syndrome, an illness characterized by pruritic painful acral erythema associated with fever and mucosal lesions (",
"    <a class=\"graphic graphic_picture graphicRef51856 \" href=\"UTD.htm?31/47/32498\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although proposed as an etiologic agent, parvovirus was not linked to Henoch-Sch&ouml;nlein purpura (IgA vasculitis) in children in one case control study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pathogenesis of parvovirus associated rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the rash associated with B19 infection is not clear. However, since it usually coincides with measurable serum antibody production, it is presumed to be at least partially immune mediated. The role of serum antibodies in rash development is also suggested by the appearance of rash after IVIG administration to immunodeficient patients with chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/40\">",
"     40",
"    </a>",
"    ]. Immune complexes have been detected during acute infection and are proposed to participate in the pathogenesis of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/32\">",
"     32",
"    </a>",
"    ]. B19 DNA and antigen have been detected in a skin biopsy specimen from a patient with EI, suggesting that direct infection of epidermal cells may also contribute to rash development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arthralgia and/or arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection can present as an acute arthritis and may be mistaken for acute rheumatoid arthritis in the absence of rash. Arthralgia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthritis are more common in adult females compared to adult males or children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/28,42\">",
"     28,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint symptoms are usually symmetric and most frequently involve the small joints of the hands, wrists, knees, and feet [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Approximately 75 percent of patients will develop a rash, although less than 20 percent will have the appearance of the typical malar (\"slapped cheeks\") rash seen in EI [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/45\">",
"     45",
"    </a>",
"    ]. Joint symptoms usually resolve in three weeks, although a minority of patients may develop persistent or recurring arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/46\">",
"     46",
"    </a>",
"    ]. The arthritis associated with acute B19 infection does not cause joint destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between juvenile chronic arthropathy and parvovirus infection was investigated in synovial tissue samples of children with juvenile idiopathic arthritis and from healthy young adults. B19 DNA was detected in synovial tissue specimens from 28 percent of children with chronic arthritis but also in 48 percent of those without chronic joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/44\">",
"     44",
"    </a>",
"    ]. The association of parvovirus DNA and chronic arthropathy in children is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pathogenesis of arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;B19 has clearly been associated with the arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthropathy that occur during the acute phase of the illness. However, the pathogenesis of joint disease is unclear. As with rash development, joint symptoms usually occur soon after the serum antibody response is measurable. Studies of individuals presenting with acute B19 arthritis have documented B19 DNA in joint fluid specimens, but not within specific cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, it is not yet clear whether viral DNA represents direct infection of the synovial tissue or systemic viremia with seeding of the joint space.",
"   </p>",
"   <p>",
"    It is possible that virus remains in lymphocytes, macrophages and follicular dendritic cells for longer periods, as has recently been suggested to occur in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/46\">",
"     46",
"    </a>",
"    ]. Viral presence in these cells may contribute to the pathogenesis of the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hematologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection can lead to transient aplastic crisis and chronic anemia, depending on the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Transient aplastic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a history of hematologic abnormalities, including increased RBC destruction (eg, sickle cell disease, hereditary spherocytosis) or decreased RBC production (eg, iron deficiency anemia), are at increased risk of developing transient aplastic crisis (TAC) secondary to parvovirus infection. In one study, B19 infection in individuals with hematologic abnormalities was associated with severe aplasia, mild hematologic changes, or no discernible change in 67, 9, and 24 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/49\">",
"     49",
"    </a>",
"    ]. Genotype 3 erythroviruses have also been associated with TAC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with TAC usually present with pallor, weakness, and lethargy secondary to severe anemia. Infection can rarely be fatal due to congestive heart failure, cerebrovascular accidents, and acute splenic sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/50\">",
"     50",
"    </a>",
"    ]. Although most of these patients will not develop a rash, they will often have an undetectable peripheral reticulocyte count and a drop in hemoglobin concentration of &gt;30 percent secondary to complete arrest of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dramatic decrease or absence of measurable reticulocytes is a hallmark laboratory finding in persons with B19 infection. A bone marrow biopsy is usually remarkable for severe aplasia. These laboratory abnormalities are associated with high viral titers of parvovirus DNA. Red cell production returns to baseline after resolution of infection. Occasionally, white cell and platelet counts may also fall during TAC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/22\">",
"     22",
"    </a>",
"    ]. TAC is usually an isolated clinical event in these patients, suggesting that recovery is associated with life-long immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anemia in immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressed patients are at risk of developing acute or chronic anemia following B19 infection due to lack of protective antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. Life-threatening anemia can develop due to the inability to mount an immune response to clear viremia. Chronic infection leads to chronic hypoplasia or aplasia of the erythroid series in the bone marrow, resulting in giant pronormoblasts and a reticulocytopenic anemia (",
"    <a class=\"graphic graphic_picture graphicRef83402 \" href=\"UTD.htm?23/33/24084\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/57\">",
"     57",
"    </a>",
"    ]. Infection is usually not accompanied by rash or arthropathy, which may be due to the inadequate immune response in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic infection and anemia have been described in the following groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/40,58-62\">",
"     40,58-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with certain leukemias or cancers",
"     </li>",
"     <li>",
"      HIV-infected patients with advanced immunodeficiency",
"     </li>",
"     <li>",
"      Patients with congenital immunodeficiencies",
"     </li>",
"     <li>",
"      Recipients of organ transplants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective review of 98 transplant recipients with parvovirus infection, the median time to onset of disease was seven weeks after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/63\">",
"     63",
"    </a>",
"    ]. Anemia, leukopenia, and thrombocytopenia occurred in 99, 38, and 21 percent of patients, respectively. Hepatitis, myocarditis and pneumonitis were also reported.",
"   </p>",
"   <p>",
"    Immunosuppressed patients respond well to intravenous immune globulin (IVIG); however, some patients require recurrent treatment for relapses. Resolution of parvovirus-induced anemia in HIV-infected patients after the initiation of highly active antiretroviral therapy has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/62,64-66\">",
"     62,64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=see_link\">",
"     \"Treatment and prevention of parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Parvovirus in malaria-endemic areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe anemia is a major cause of death among young children in developing countries and may be due to a variety of causes, including malaria, iron deficiency, and hookworm infections. In a study of 169 children in Papua New Guinea with severe anemia (six months to five years old), archival blood samples were studied for the presence of B19 immunoglobulin IgM by enzyme immunoassay and for B19 DNA by polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/67\">",
"     67",
"    </a>",
"    ]. A strong association between acute B19 infection and severe anemia was demonstrated when compared to controls matched for sex and age (odds ratio 5.6). In a multivariate analysis, acute B19 infection was associated with an increase in the risk of severe anemia comparable to that associated with Plasmodium falciparum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pathogenesis of anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of anemia is due to destruction of erythrocyte progenitor cells, which dramatically reduces red cell production. During an acute infection, this results in a significant drop in hematocrit. In healthy individuals, RBC production returns in 10 to 14 days with little anemia.",
"   </p>",
"   <p>",
"    However, in individuals with an increased RBC turnover, even a limited cessation of RBC production can lead to a clinically significant drop in hemoglobin and transient aplastic crisis (TAC). In patients unable to control B19 infection because of immunosuppression or immunodeficiency, lysis of RBC precursors leads to prolonged cessation of RBC production and the development of a severe, chronic pure red cell aplasia and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Non-immune hydrops fetalis and intrauterine fetal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;B19 infection during pregnancy can result in fetal complications including miscarriage, intrauterine fetal death",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-immune hydrops fetalis. Because of this potential, it is critical to determine the serologic status of the pregnant woman who has a history of significant exposure to the virus or who has any of the classic symptoms of B19 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=see_link\">",
"     \"Parvovirus B19 infection during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus is especially susceptible to the effects of B19-induced anemia due to its shortened RBC half-life and the expanding RBC volume. The relatively immature fetal immune system is also less able to effectively control virus infection. The ensuing fetal hydrops appears to result from the onset of severe anemia, which in turn causes high output heart failure. Fetal B19 infection can also present with thrombocytopenia. However, fetal bleeding was not seen as a complication of the low platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infection has been associated with myocarditis, dilated cardiomyopathy, and isolated left ventricular diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In a study of 172 consecutive patients with myocarditis, endomyocardial biopsies demonstrated the presence of enterovirus, adenovirus, parvovirus, or human herpesvirus type 6 by polymerase chain reaction in 33, 8, 37, and 11 percent of samples [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/70\">",
"     70",
"    </a>",
"    ]. Follow-up analysis of subsequent biopsies documented spontaneous clearance of viral genomes in 36 percent of all patients with single infections, which was associated with improvement in left ventricular ejection fraction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study examined the possibility of asymptomatic B19 DNA persistence in heart tissue. Myocardial tissues and blood samples taken randomly at 69 autopsies were analyzed by PCR and serology, respectively. B19 DNA was found in myocardial tissues from 46 of 48 (95.8 percent) of the seropositive cases, but in none of the 21 seronegative cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/73\">",
"     73",
"    </a>",
"    ]. Their findings suggest that detecting B19 DNA in myocardial tissue alone is not sufficient to suggest a cause and effect.",
"   </p>",
"   <p>",
"    Fatal myocarditis secondary to parvovirus B19 infection has also been described in a liver transplant recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;B19 has been reported in association with a wide range of diseases and clinical manifestations, including arthritis, vasculitis, myocarditis, nephritis, lymphadenitis, immune thrombocytopenia (ITP), meningitis and encephalitis, hemophagocytic syndrome, fulminant liver disease, and generalized edema, as well as many other conditions (",
"    <a class=\"graphic graphic_table graphicRef62492 \" href=\"UTD.htm?22/56/23437\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/75-83\">",
"     75-83",
"    </a>",
"    ]. The association with acute hepatitis has been refuted in a subsequent study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/84\">",
"     84",
"    </a>",
"    ]. The strength of the association of these diseases with parvovirus is frequently difficult to evaluate because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some B19-specific serologic assays have the potential for false-positive B19 IgM antibody, false-negative IgG antibody results, or cross-reactivity with antibodies to other infectious agents or rheumatoid factor. It is well established that for better accuracy, the B19-specific IgG enzyme immunoassay should incorporate a conformational capsid antigen. This is based on the fact that circulating IgG antibodies directed against linear epitopes of the capsid antigens gradually decline postinfection; however, B19-specific IgG directed against conformational epitopes of those capsid antigens are maintained long term [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      B19 DNA can remain detectable by nucleic acid amplification testing (NAAT) for extended periods after infection without evidence of disease in some individuals.",
"     </li>",
"     <li>",
"      False-positive B19 DNA NAAT results from laboratory contamination can occur, especially when using a nested PCR testing approach, or a non-real-time PCR assay.",
"     </li>",
"     <li>",
"      Parvovirus B19 is a recognized cause of isolated angioedema in neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22377/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13394?source=see_link\">",
"       \"Patient information: Erythema infectiosum (fifth disease) (The Basics )\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parvovirus B19 was first associated with a clinical disease in 1981. Infection can lead to a variety of clinical manifestations dependent on the underlying host. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvovirus B19 is a single stranded DNA virus that is associated with a wide variety of clinical manifestations, some being more common than others. The virus replicates in erythroid progenitor cells of the bone marrow and blood leading to inhibition of erythropoiesis. The observed tropism of parvovirus is most likely due to the distribution of its cellular receptor, P blood group antigen, globoside, which is found in high concentrations on red blood cells and their precursors. In addition, two co-receptors, the auto-antigen Ku80 and alpha 5 beta 1 integrin, have been shown to participate in viral binding and entry into cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viremia occurs one week after exposure and usually lasts approximately five days, with virus titers peaking on the first few days of infection. Development of a robust antibody response corresponds to viral clearance and subsequent protection from disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immunology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentations associated with B19 infection vary greatly, ranging from benign to life threatening. The clinical presentation is influenced by the infected individual's age and hematologic and immunologic status. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some adults may have non-specific constitutional symptoms followed by more characteristic findings of rash, arthralgia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      edema. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, erythema infectiosum (EI) begins with nonspecific prodromal symptoms, followed by a classic erythematous malar rash and lacy appearance on the extremities. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Erythema infectiosum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults, parvovirus B19 infection can present as an acute arthritis with edema in the extremities and may be mistaken for acute rheumatoid arthritis in the absence of rash. Joint symptoms are usually symmetric and most frequently involve the small joints of the hands, wrists, knees, and feet. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Arthralgia and/or arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvovirus B19 infection can lead to transient aplastic crisis in patients with increased RBC turnover (eg, patients with sickle cell anemia). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hematologic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunosuppressed patients, such as HIV-infected patients, can develop severe chronic anemia due to lack of neutralizing antibody responses against parvovirus. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anemia in immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      B19 infection during pregnancy can result in fetal complications including miscarriage, intrauterine fetal death",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      non-immune hydrops fetalis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Non-immune hydrops fetalis and intrauterine fetal death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/1\">",
"      Virus taxonomy update. The International Committee on Taxonomy of Viruses. Arch Virol 1993; 133:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/2\">",
"      Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/3\">",
"      Nguyen QT, Sifer C, Schneider V, et al. Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/4\">",
"      Nguyen QT, Wong S, Heegaard ED, Brown KE. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/5\">",
"      Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76:9124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/6\">",
"      Norja P, Eis-H&uuml;binger AM, S&ouml;derlund-Venermo M, et al. Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections. J Virol 2008; 82:6427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/7\">",
"      Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol 2007; 88:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/8\">",
"      Moffatt S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70:8485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/9\">",
"      Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci U S A 2004; 101:11628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/10\">",
"      Mortimer PP, Humphries RK, Moore JG, et al. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 1983; 302:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/11\">",
"      Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/12\">",
"      Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/13\">",
"      Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/14\">",
"      Rouger P, Gane P, Salmon C. Tissue distribution of H, Lewis and P antigens as shown by a panel of 18 monoclonal antibodies. Rev Fr Transfus Immunohematol 1987; 30:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/15\">",
"      Jordan JA, Butchko AR. Apoptotic activity in villous trophoblast cells during B19 infection correlates with clinical outcome: assessment by the caspase-related M30 Cytodeath antibody. Placenta 2002; 23:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/16\">",
"      Moffatt S, Yaegashi N, Tada K, et al. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72:3018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/17\">",
"      Ozawa K, Ayub J, Kajigaya S, et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/18\">",
"      Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 2001; 75:4110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/19\">",
"      Kaufmann B, Baxa U, Chipman PR, et al. Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology 2005; 332:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/20\">",
"      Weigel-Kelley KA, Yoder MC, Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 2003; 102:3927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/21\">",
"      Munakata Y, Saito-Ito T, Kumura-Ishii K, et al. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 2005; 106:3449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/22\">",
"      Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/23\">",
"      Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol 2001; 8:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/24\">",
"      Lower FE, Menon S, Sanchez JA. Association of parvovirus B19 with plasma cell-rich myocardial infiltrates after heart transplantation. J Heart Lung Transplant 2001; 20:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/25\">",
"      von Poblotzki A, Gerdes C, Reischl U, et al. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70:7327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/26\">",
"      Wagner AD, Goronzy JJ, Matteson EL, Weyand CM. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995; 70:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/27\">",
"      Norbeck O, Isa A, P&ouml;hlmann C, et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005; 79:12117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/28\">",
"      Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/29\">",
"      Hayakawa H, Tara M, Niina K, Osame M. A clinical study of adult human parvovirus B19 infection. Intern Med 2002; 41:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/30\">",
"      Waza K, Inoue K, Matsumura S. Symptoms associated with parvovirus B19 infection in adults: a pilot study. Intern Med 2007; 46:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/31\">",
"      Chorba T, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/32\">",
"      Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/33\">",
"      Waldman M, Kopp JB. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol 2007; 2 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/34\">",
"      Anderson LJ. Role of parvovirus B19 in human disease. Pediatr Infect Dis J 1987; 6:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/35\">",
"      Lindblom A, Isa A, Norbeck O, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 2005; 41:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/36\">",
"      Lowry SM, Brent LH, Menaldino S, Kerr JR. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. Clin Infect Dis 2005; 41:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/37\">",
"      Boeck K, Mempel M, Schmidt T, Abeck D. Gianotti-Crosti syndrome: clinical, serologic, and therapeutic data from nine children. Cutis 1998; 62:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/38\">",
"      Grilli R, Izquierdo MJ, Fari&ntilde;a MC, et al. Papular-purpuric \"gloves and socks\" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 1999; 41:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/39\">",
"      Heegaard ED, Taaning EB. Parvovirus B19 and parvovirus V9 are not associated with Henoch-Sch&ouml;nlein purpura in children. Pediatr Infect Dis J 2002; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/40\">",
"      Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/41\">",
"      Schwarz TF, Wiersbitzky S, Pambor M. Case report: detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/42\">",
"      Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 2000; 27:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/43\">",
"      O��uz F, Akdeniz C, Un&uuml;var E, et al. Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J Paediatr Child Health 2002; 38:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/44\">",
"      S&ouml;derlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/45\">",
"      Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/46\">",
"      Nikkari S, Roivainen A, Hannonen P, et al. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis 1995; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/47\">",
"      Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998; 16:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/48\">",
"      Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95:8227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/49\">",
"      Serjeant BE, Hambleton IR, Kerr S, et al. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/50\">",
"      Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/51\">",
"      Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/52\">",
"      Aguiar FS, Lopes DP, Bazin AR, et al. Human parvovirus B19 infection in HIV-positive patients. Rev Soc Bras Med Trop 2001; 34:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/53\">",
"      Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol 1998; 31:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/54\">",
"      Heegaard ED, Schmiegelow K. Serologic study on parvovirus b19 infection in childhood acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J Pediatr Hematol Oncol 2002; 24:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/55\">",
"      Moreux N, Ranchin B, Calvet A, et al. Chronic parvovirus B19 infection in a pediatric lung transplanted patient. Transplantation 2002; 73:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/56\">",
"      Kurtzman GJ, Cohen B, Meyers P, et al. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988; 2:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/57\">",
"      Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol 1997; 53:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/58\">",
"      Vales-Albertos LJ, Garc&iacute;a-C&aacute;rdenas M, Ch&aacute;vez-Becerra S, et al. Pure red cell aplasia associated with parvovirus B19 infection in renal transplantation: the first case report in Mexico. Transplantation 2005; 79:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/59\">",
"      Plentz A, Hahn J, Holler E, et al. Long-term parvovirus B19 viraemia associated with pure red cell aplasia after allogeneic bone marrow transplantation. J Clin Virol 2004; 31:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/60\">",
"      Fattet S, Cassinotti P, Popovic MB. Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia. J Pediatr Hematol Oncol 2004; 26:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/61\">",
"      Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS 2000; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/62\">",
"      Chen MY, Hung CC, Fang CT, Hsieh SM. Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy. Clin Infect Dis 2001; 32:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/63\">",
"      Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/64\">",
"      Ware AJ, Moore T. Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2001; 32:E122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/65\">",
"      Arribas JR, Pe&ntilde;a JM, Echevarr&iacute;a JE. Parvovirus B19-related anemia in an HIV-infected patient: rapid control after production of neutralizing antibodies during highly active antiretroviral therapy. Ann Intern Med 2000; 132:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/66\">",
"      Mylonakis E, Dickinson BP, Mileno MD, et al. Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy. Am J Hematol 1999; 60:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/67\">",
"      Wildig J, Michon P, Siba P, et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis 2006; 194:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/68\">",
"      Morgan-Capner P, Crowcroft NS, PHLS Joint Working Party of the Advisory Committees of Virology and Vaccines and Immunisation. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun Dis Public Health 2002; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/69\">",
"      de Haan TR, van den Akker ES, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/70\">",
"      K&uuml;hl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/71\">",
"      Tsch&ouml;pe C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/72\">",
"      Donoso Mantke O, Nitsche A, Meyer R, et al. Analysing myocardial tissue from explanted hearts of heart transplant recipients and multi-organ donors for the presence of parvovirus B19 DNA. J Clin Virol 2004; 31:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/73\">",
"      Schenk T, Enders M, Pollak S, et al. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J Clin Microbiol 2009; 47:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/74\">",
"      Jonetzko P, Graziadei I, Nachbaur K, et al. Fatal course of parvovirus B19-associated myocarditis in a female liver transplant recipient. Liver Transpl 2005; 11:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/75\">",
"      Finkel TH, T&ouml;r&ouml;k TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/76\">",
"      Heegaard ED, Eiskjaer H, Baandrup U, Hornsleth A. Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand J Infect Dis 1998; 30:607.",
"     </a>",
"    </li>",
"    <li>",
"     Torok TJ. Unusual clinical manifestations reported in patients with parvovirus B19 infection. In: Monographs in Virology: Human Parvovirus B19, Anderson LJ, Young NS (Eds), Karger, New York 1997. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/78\">",
"      Kn&ouml;sel T, Meisel H, Borgmann A, et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005; 58:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/79\">",
"      Alvarez-Lafuente R, Fern&aacute;ndez-Guti&eacute;rrez B, Jover JA, et al. Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 2005; 64:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/80\">",
"      Aktepe OC, Yetgin S, Olcay L, Ozbek N. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2004; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/81\">",
"      Shirono K, Tsuda H. Parvovirus B19-associated haemophagocytic syndrome in healthy adults. Br J Haematol 1995; 89:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/82\">",
"      Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009; 48:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/83\">",
"      Wiggli B, Imhof E, Meier CA, Laifer G. Water, water, everywhere. Lancet 2013; 381:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/84\">",
"      Lee WM, Brown KE, Young NS, et al. Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci 2006; 51:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/85\">",
"      Jordan JA. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J Clin Microbiol 2000; 38:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/86\">",
"      Kerr S, O'Keeffe G, Kilty C, Doyle S. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J Med Virol 1999; 57:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22377/abstract/87\">",
"      Miyagawa S, Takahashi Y, Nagai A, et al. Angio-oedema in a neonate with IgG antibodies to parvovirus B19 following intrauterine parvovirus B19 infection. Br J Dermatol 2000; 143:428.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8272 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22377=[""].join("\n");
var outline_f21_54_22377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMUNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ISSUES OF INFECTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erythema infectiosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pathogenesis of parvovirus associated rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arthralgia and/or arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pathogenesis of arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hematologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Transient aplastic crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anemia in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Parvovirus in malaria-endemic areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pathogenesis of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Non-immune hydrops fetalis and intrauterine fetal death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other disease associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8272\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8272|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/45/30430\" title=\"figure 1\">",
"      Course of acute B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8272|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26895\" title=\"picture 1A\">",
"      Slapped cheek rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/27/11696\" title=\"picture 1B\">",
"      Rash in erythema infectiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/47/32498\" title=\"picture 2\">",
"      Gloves and socks syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/33/24084\" title=\"picture 3\">",
"      Bone marrow biopsy in parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8272|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/27/17851\" title=\"table 1\">",
"      B19 symptoms in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/56/23437\" title=\"table 2\">",
"      B19 associated conditions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32312?source=related_link\">",
"      Epidemiology and laboratory diagnosis of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40408?source=related_link\">",
"      Parvovirus B19 infection during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13394?source=related_link\">",
"      Patient information: Erythema infectiosum (fifth disease) (The Basics )",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31767?source=related_link\">",
"      Treatment and prevention of parvovirus B19 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22378="Microbiology and pathogenesis of tuberculosis";
var content_f21_54_22378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and pathogenesis of tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22378/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22378/contributors\">",
"     Lee W Riley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22378/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/54/22378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/54/22378/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/54/22378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterium tuberculosis is the second most common infectious cause of death in adults worldwide (HIV is the most common). The human host serves is the natural reservoir for M. tuberculosis. The ability of the organism to efficiently establish latent infection has enabled it to spread to nearly one-third of individuals worldwide. Approximately 8 million new cases of active TB disease occur each year, leading to about 1.7 million deaths. The disease incidence is magnified by the concurrent epidemic of human immunodeficiency virus (HIV) infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The microbiology and pathogenesis of M. tuberculosis will be reviewed here. The immunology of this infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43289?source=see_link\">",
"     \"Immunology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13826069\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation of M. tuberculosis and deposition in the lungs leads to one of four possible outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate clearance of the organism",
"     </li>",
"     <li>",
"      Latent infection",
"     </li>",
"     <li>",
"      Immediate onset of active disease (primary disease)",
"     </li>",
"     <li>",
"      Onset of active disease many years following exposure (reactivation disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among individuals with latent infection and no underlying medical problems, reactivation disease occurs in approximately 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of reactivation is markedly increased in patients with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/2\">",
"     2",
"    </a>",
"    ]. These outcomes are determined by the interplay of factors attributable to both the organism and the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13826076\">",
"    <span class=\"h2\">",
"     Primary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of our understanding of the natural course of tuberculosis (TB) comes from human autopsy data prior to the era of antituberculosis drugs and from experimental animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Among the approximately 10 percent of infected individuals who develop active disease, approximately one-half of them will do so within the first two to three years following infection; such individuals are said to develop rapidly progressive or primary disease.",
"   </p>",
"   <p>",
"    The tubercle bacilli establish infection in the lungs after they are carried in droplets small enough (5 to 10 micron) to reach the alveolar space. If the innate defense system of the host fails to eliminate the infection, the bacilli proliferate inside alveolar macrophages and eventually kill the cells. The infected macrophages produce cytokines and chemokines that attract other phagocytic cells, including monocytes, other alveolar macrophages, and neutrophils, which eventually form a nodular granulomatous structure called the tubercle. If the bacterial replication is not controlled, the tubercle enlarges and the bacilli enter local draining lymph nodes. This leads to lymphadenopathy, a characteristic manifestation of primary TB. The lesion produced by the expansion of the tubercle into the lung parenchyma and lymph node involvement is called the Ghon complex. Bacteremia may accompany initial infection.",
"   </p>",
"   <p>",
"    The bacilli continue to proliferate until an effective cell-mediated immune (CMI) response develops, usually two to six weeks after infection. Failure by the host to mount an effective CMI response and tissue repair leads to progressive destruction of the lung. Tumor necrosis factor (TNF)-alpha, reactive oxygen and nitrogen intermediates, and the contents of cytotoxic cells (granzymes, perforin) may all contribute to the development of caseating necrosis that characterizes a tuberculous lesion. Caseous necrosis is frequently associated with TB but can also be caused by other organisms, including syphilis, histoplasmosis, cryptococcosis, and coccidioidomycosis. (See related topics).",
"   </p>",
"   <p>",
"    Unchecked bacterial growth may lead to hematogenous spread of bacilli to produce disseminated TB. Disseminated disease with lesions resembling millet seeds has been termed miliary TB. Bacilli can also spread mechanically by erosion of the caseating lesions into the lung airways; at this point the host becomes infectious to others. In the absence of treatment, death ensues in 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/8\">",
"     8",
"    </a>",
"    ]. The remaining patients develop chronic disease or recover. Chronic disease is characterized by repeated episodes of healing by fibrotic changes around the lesions and tissue breakdown. Complete spontaneous eradication of the bacilli is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13826083\">",
"    <span class=\"h2\">",
"     Reactivation disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation TB results from proliferation of a previously dormant bacteria seeded at the time of the primary infection. Among individuals with latent infection and no underlying medical problems, reactivation disease occurs in approximately 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/1\">",
"     1",
"    </a>",
"    ]. Immunosuppression is clearly associated with reactivation TB, although it is not clear what specific host factors maintain the infection in a latent state and what triggers the latent infection to become overt. Immunosuppressive conditions associated with reactivation TB include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV infection and AIDS",
"     </li>",
"     <li>",
"      End-stage renal disease",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Malignant lymphoma",
"     </li>",
"     <li>",
"      Corticosteroid use",
"     </li>",
"     <li>",
"      Inhibitors of TNF-alpha and its receptor",
"     </li>",
"     <li>",
"      Diminution in cell mediated immunity associated with age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disease process in reactivation TB tends to be localized (in contrast to primary disease); there is little regional lymph node involvement and less caseation. The lesion typically occurs at the lung apices, and disseminated disease is unusual, unless the host is severely immunosuppressed.",
"   </p>",
"   <p>",
"    It is generally believed that successfully contained latent tuberculosis confers protection against subsequent TB exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/9\">",
"     9",
"    </a>",
"    ]. One review evaluating 23 paired cohorts (total more than 19,000 individuals) noted that individuals with latent tuberculosis had 79 percent lower risk of progressive tuberculosis following reinfection compared with uninfected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/10\">",
"     10",
"    </a>",
"    ]. However, successful treatment for TB may not always confer protection against a subsequent episode of TB. In one study from South Africa including 612 patients treated for TB, recurrence was observed in 18 percent of cases over a five-year follow-up period; recurrence occurred after successful treatment in 14 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/11\">",
"     11",
"    </a>",
"    ]. By comparing DNA fingerprints of the M. tuberculosis isolates from the first and second episodes of TB, the investigators showed that 77 percent of the recurrences were new infections rather than relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/11\">",
"     11",
"    </a>",
"    ]. The rate of reinfection TB was four times the rate of new TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. tuberculosis belongs to the genus Mycobacterium that includes more than 50 other species, often collectively referred to as nontuberculous mycobacteria. Tuberculosis (TB) is defined as a disease caused by members of the M. tuberculosis complex, which includes the tubercle bacillus (M. tuberculosis), M. bovis, M. africanum, M. microti, M. canetti, M. caprae, and M. pinnipedii [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cell envelope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cell envelope is a distinguishing feature of the organisms belonging to the genus Mycobacterium. Unlike gram-negative bacteria, there is no true outer membrane in Mycobacterium. The mycobacterial cell envelope is composed of a core of three macromolecules covalently linked to each other (peptidoglycan, arabinogalactan, and mycolic acids) and a lipopolysaccharide, lipoarabinomannan (LAM), which is thought to be anchored to the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mycolic acid, a beta-hydroxy fatty acid, is the major constituent of the cell envelope, accounting for more than 50 percent by weight; this structure defines the genus. Glycolipids are attached to the outside of the envelope layer through a connection to the mycolic acid layer; proteins are also embedded in this cell wall complex. Glycolipid components are implicated in \"cord formation,\" whereby tuberculosis bacilli clump together forming a serpiginous structure seen on microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Staining characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cell wall components give Mycobacterium its characteristic staining properties. The organism stains positive with Gram's stain. The mycolic acid structure confers the ability to resist destaining by acid alcohol after being stained by certain aniline dyes, leading to the term acid fast bacillus (AFB).",
"   </p>",
"   <p>",
"    Microscopy to detect AFB (using Ziehl-Neelsen or Kinyoun stain) is the most commonly used procedure to diagnose TB; a specimen must contain at least 10(4) colony forming units",
"    <span class=\"nowrap\">",
"     (CFU)/mL",
"    </span>",
"    to yield a positive smear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/15\">",
"     15",
"    </a>",
"    ]. Microscopy of specimens stained with a fluorochrome dye (such as auramine O provides) an easier, more efficient, and more sensitive alternative. However, microscopic detection of mycobacteria does not distinguish M. tuberculosis from nontuberculous mycobacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Growth characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinguishing feature of M. tuberculosis is its slow growth rate. In artificial media and animal tissues, its generation time is about 20 to 24 hours (as opposed to 20 minutes for organisms such as Escherichia coli).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Isolation in the laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial media used to cultivate M. tuberculosis include potato and egg base media, such as Middlebrook 7H10 or 7H11, or albumin in an agar base, such as the Lowenstein-Jensen (LJ) medium [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/16\">",
"     16",
"    </a>",
"    ]. A liquid medium, such as Middlebrook 7H9, is used for subcultures and for propagating the bacillus to extract DNA for molecular diagnostic and strain typing procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/17\">",
"     17",
"    </a>",
"    ]. Three to four weeks are required to recover the organism, depending upon the initial quantity of organisms in the specimen.",
"   </p>",
"   <p>",
"    Broth-based culture systems to improve the speed and sensitivity of detection have been developed. The BACTEC (BC Diagnostics, Sparks, MD) system is based upon Middlebrook 7H12 medium containing 14C palmitic acid with a mixture of antibiotics (PANTA) to suppress other bacterial growth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/18\">",
"     18",
"    </a>",
"    ]. The addition of NAP (p-nitro-alpha-acetylamino-beta-hydroxypropiophenone) in the medium suppresses growth of other M. tuberculosis complex organisms, such as M. bovis, but does not differentiate M. tuberculosis from other nontuberculous mycobacteria.",
"   </p>",
"   <p>",
"    Bacterial growth is indicated by the detection of 14C released by M. tuberculosis as it metabolizes the palmitic acid. In AFB smear-positive specimens, the BACTEC system can detect M. tuberculosis in approximately eight days (compared to approximately 14 days for smear-negative specimens) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, the high cost of the equipment and the need for radioactive material that requires disposal exclude its use in most endemic settings.",
"   </p>",
"   <p>",
"    Other broth-based systems include Septi-Chek AFB (BBL) and the Mycobacterial Growth Indicator Tube (MGIT, BD Diagnostics) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Septi-Chek AFB is a biphasic system comprised of a capped bottle containing modified Middlebrook 7H9 broth under CO2 and a paddle coated with solid agar, such as Middlebrook 7H11 and LJ media [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/21\">",
"     21",
"    </a>",
"    ]. The recovery rate of M. tuberculosis complex from AFB smear-negative specimens by this procedure is about 15 to 30 percent higher than conventional media and the average number of days to recovery is two to five days shorter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MGIT is based on Middlebrook 7H9 broth containing silicon rubber impregnated with ruthenium pentahydrate that serves as a fluorescence quenching-oxygen sensor. As oxygen is consumed by metabolizing bacteria, fluorescence of the liquid growth medium is detected visually. Among smear-negative samples in a study of 1500 clinical specimens, the recovery rate of the M. tuberculosis complex was about 15 percent less by the MGIT system (68 percent) compared to that obtained by the radiometric BACTEC system, but the mean time to detection was similar (9.9 versus 9.7 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/22\">",
"     22",
"    </a>",
"    ]. The lack of need for expensive instrumentation and radioactive materials should render MGIT widely acceptable and suitable in many laboratories.",
"   </p>",
"   <p>",
"    A similar broth-based and colorimetric detection system is the",
"    <span class=\"nowrap\">",
"     MB/BacT",
"    </span>",
"    system (bioM&eacute;rieux, Durham, NC). In this system, a colorimetric sensor is embedded at the bottom of a bottle, and when carbon dioxide is produced by a growing microorganism, the sensor changes from dark green to yellow. This change in color is monitored continuously by a detection device. A systematic review of this system (compared with the BACTEC 460) found that the",
"    <span class=\"nowrap\">",
"     MB/BacT",
"    </span>",
"    system had a sensitivity of 96 to 100 percent and a specificity of 78 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Versa TREK (Trek Diagnostic Systems, West Lake, Ohio) system is an automated detection system based on discerning a change in gas pressure (oxygen consumption by a growing microorganism) in a sealed container. The systematic review comparing Versa TREK with BACTEC-460, found a sensitivity from 82 to 100 percent and a specificity of 50 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A continuous automated mycobacterial liquid culture system (CAMLiC) has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/24\">",
"     24",
"    </a>",
"    ]. This system is more sensitive than LJ culture in identifying M. tuberculosis complex organisms (98 versus 85 to 90 percent) with a mean time to recovery of 13.4 days. It has not been compared yet to BACTEC, Septi-Chek AFB, or MGIT and is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Identification of the organism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the organism is isolated, identification is based upon morphologic and biochemical characteristics, although nucleic acid-based detection methods have obviated many of the conventional tests. M. tuberculosis is identified by its rough, nonpigmented, so-called corded colonies on albumin-based agars. It is typically positive in the niacin test, has a weak catalase activity, which is inactivated at 68&ordm;C, and reduces nitrate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\", section on 'Nucleic acid amplification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only other major slow-growing mycobacterium that is niacin test-positive is M. simiae. Although all members of the mycobacteria species produce niacin (usually undetectable by the niacin test), the differences in the activity of the enzymes involved in the salvage pathway of NAD biosynthesis in M. tuberculosis determines niacin positivity in M. tuberculosis. Niacin accumulates in M. tuberculosis because nicotinamidase that converts nicotinamide to niacin is several-fold more active, and the enzyme that recycles niacin to produce NAD is less active than in members of most other mycobacterial species [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The niacin, nitrate reductase, and catalase tests are the three biochemical tests most frequently used to distinguish M. tuberculosis from other mycobacterial species [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/16\">",
"     16",
"    </a>",
"    ]. Tests for pyrazinamidase production as well as susceptibility to thiophen-2-carboxylic acid hydrazide (TCH) will distinguish M. tuberculosis from M. bovis, another member of the M. tuberculosis complex. M. bovis does not express pyrazinamidase (or nicotinamidase) and is susceptible to less than 5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of TCH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. Clinical isolates of M. tuberculosis lacking pyrazinamidase activity have been described which contain nucleotide point mutations in the gene (pncA) that encodes pyrazinamidase; these isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    (PZA), one of the first-line drugs used to treat TB [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug susceptibility tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug susceptibility testing is of growing importance with emergence of increasingly resistant M. tuberculosis isolates. Drug-resistant tuberculosis refers to M. tuberculosis that is resistant to one of the first-line antituberculosis drugs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    . Multidrug-resistant tuberculosis (MDR-TB) refers to M. tuberculosis that is resistant to at least isoniazid and rifampin, and possibly additional chemotherapeutic agents. Extensively drug-resistant TB (XDRTB) refers to M. tuberculosis resistant to at least isoniazid and rifampin as well as at least one of three injectable second-line drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ) and a fluoroquinolone.",
"   </p>",
"   <p>",
"    In addition to the conventional methods to test M. tuberculosis drug susceptibility, methods that rely utilizing automated systems and PCR-based tests have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In automated systems (BACTEC and the others), growth detected by the indicator system in drug-containing broth is interpreted as resistance to the drug. A colorimetric microplate-based Alamar Blue assay evaluated in Peru for 34 M. tuberculosis isolates was comparable with the BACTEC drug-susceptibility test (88 to 94 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/30\">",
"     30",
"    </a>",
"    ]. The test is based on colorimetric determination of an oxidation-reduction indicator dye resazurin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microscopic observation drug susceptibility (MODS) test is another liquid culture based drug-susceptibility test based on observation of M. tuberculosis growth in liquid broth medium containing a test drug. Culture aliquots are examined daily via inverted light microscopy for cording, a characteristic growth pattern of M. tuberculosis but not non-tuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/32\">",
"     32",
"    </a>",
"    ]. Absence of growth or cording indicates susceptibility to the broth test drug. In an evaluation of 3760 sputum samples using MODS, automated",
"    <span class=\"nowrap\">",
"     MB/BacT",
"    </span>",
"    system, and L&ouml;wenstein-Jensen culture, sensitivity was 98, 89, and 84 percent, respectively and the median time to the test results was 7, 22, and 68 days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/33\">",
"     33",
"    </a>",
"    ]. The agreement between MODS and the reference tests for susceptibility was high for all standard anti-tuberculosis drugs.",
"   </p>",
"   <p>",
"    Line-probe assays (such as InnoLiPA and GenoTypeMTBDR) are gene probe assays to detect drug-resistant M. tuberculosis; these combine hybridization assays and a nucleic acid amplification test, such as PCR. The PCR target is the M. tuberculosis rpoB gene; mutation of this gene is associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance, which is used as a surrogate for multidrug resistance (rifampin monoresistance is uncommon). Meta-analyses of these assays have noted high sensitivity and specificity for rifampin resistance of culture isolates (&gt;95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Sensitivity decreases for direct clinical specimens, such as sputum. Results can be obtained the same day if the test is performed on isolated M. tuberculosis, or if the clinical specimen (eg, sputum) contained a large number of the tubercle bacilli.",
"   </p>",
"   <p>",
"    The Xpert",
"    <span class=\"nowrap\">",
"     MTB/RIF",
"    </span>",
"    is an integrated system that combines sample preparation in a modular cartridge system and real-time PCR. In 2010 this technique was recommended by the WHO to be used in place of traditional smear microscopy for diagnosis drug-resistant TB or TB in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In various validation studies in both developed and developing countries, this test has been shown to have a sensitivity of &gt;98 percent in sputum smear-positive TB cases and 75 to 90 percent in smear-negative TB cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The sensitivity in the detection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -resistant M. tuberculosis exceeded 97 percent, while specificity ranged 98 to 100 percent in differentiating TB or rifampin-resistant TB. The test can yield results in less than two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Here, rifampin resistance is assessed as a surrogate for multidrug-resistant M. tuberculosis.",
"   </p>",
"   <p>",
"    Mycobacteriophages carrying reporter luciferase have been evaluated for the detection and susceptibility testing of M. tuberculosis. In an evaluation of 50 isolates in Mexico, the overall agreement with the BACTEC method was 98.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/40\">",
"     40",
"    </a>",
"    ]. Using the cultured organisms, the median susceptibility turnaround time was two days (10 days with BACTEC). A PCR-based method using molecular beacons (fluorogenic reporter molecules) is a promising rapid method to detect drug-resistant strains of M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/41\">",
"     41",
"    </a>",
"    ]. However, these methods are not clinically available due to cost and stability of the reagents.",
"   </p>",
"   <p>",
"    Another mycobacteriophage-based system relies on the ability of phage to infect M. tuberculosis present in a sputum sample [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/42\">",
"     42",
"    </a>",
"    ]. In this test, decontaminated sputum samples are incubated with a suspension of target-specific bacteriophage. The phage replicates within the infected bacilli, if present, and lyses them. The suspension containing released phages is incubated with fast growing, non-pathogenic mycobacteria (M. smegmatis) helper cells on an agar plate. The released mycobacteriophages infect, replicate, and lyse these helper cells to form clear zones (plaques) of cell lysis, which indicate the presence of M. tuberculosis in the original specimen. If this assay is done in the presence of an antimicrobial agent, the presence of plaques suggests drug resistance of the organism present in the clinical specimen. A meta-analysis of 13 studies evaluating mycobacteriophage-based tests demonstrated that the tests had high specificity (83 to 100 percent) but variable sensitivity (21 to 88 percent) compared to culture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete genome sequence of M. tuberculosis strain H37Rv has been determined and is annotated (",
"    <a class=\"external\" href=\"file://www.sanger.ac.uk/Projects/M_tuberculosis/\">",
"     www.sanger.ac.uk/Projects/M_tuberculosis/",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/46\">",
"     46",
"    </a>",
"    ]. The following characteristics have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genome has 4,411,529 base pairs, containing about 4,000 genes, with a G+C content of 65.6 percent.",
"     </li>",
"     <li>",
"      Consistent with the recognized structure of its cell envelope, many genes are devoted to lipid biosynthesis and metabolism.",
"     </li>",
"     <li>",
"      The organism contains lipid and polyketide biosynthetic enzymes that are normally found in mammals and plants, and about 250 enzymes involved in fatty acid degradation.",
"     </li>",
"     <li>",
"      It has only 11 complete pairs of two-component regulatory systems, as opposed to more than 30 such pairs in organisms like E. coli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 10 percent of the genes in M. tuberculosis are devoted to the production of two families of glycine-rich proteins called PE (proline-glutamine motifs) and PPE (proline-proline-glutamine motifs). These genes are composed of polymorphic GC-rich repetitive sequences (PGRSs) and major polymorphic tandem repeats, which have served as a basis for strain-typing M. tuberculosis clinical isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The functions of these families of proteins are unknown. However, the",
"    <span class=\"nowrap\">",
"     PE/PGRS",
"    </span>",
"    genes in Mycobacterium marinum, the cause of fish and amphibian tuberculosis, are preferentially expressed inside granulomas and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of approaches to study M. tuberculosis virulence have been devised, including those examining M. tuberculosis virulence factors, bacterial factors associated with intracellular survival, and genotypic differences in the community prevalence of clinical strains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following M. tuberculosis products were described as virulence factors prior to the introduction of molecular biology tools to study M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mycolic acid glycolipids and trehalose dimycolate (\"cord factor\"), which can elicit granuloma formation in animal tissue",
"     </li>",
"     <li>",
"      Catalase-peroxidase, which resists the host cell oxidative response",
"     </li>",
"     <li>",
"      Sulfatides and trehalose dimycolate, which can trigger toxicity in animal models",
"     </li>",
"     <li>",
"      Lipoarabinomannan (LAM), which can induce cytokines and resist host oxidative stress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These products and their variants are found in many members of the Mycobacterium species, so their specific role in M. tuberculosis pathogenesis is not clear.",
"   </p>",
"   <p>",
"    Many additional so-called virulence factors have been identified by molecular biology techniques. These factors are often defined as virulence factors based on comparison with the wild type M. tuberculosis strain, in which disruption of these molecules leads to (1) diminished ability of the mutant to attach to or enter mammalian cells in vitro, (2) decreased growth in vitro in artificial medium or inside mammalian cells, (3) attenuation in an animal infection model, (4) decreased ability to induce cytokines in macrophages infected ex vivo, and (5) inability to induce changes (eg, inhibition of cell physiology) in cellular targets outside of itself [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One common approach to study virulence phenotype of an intracellular pathogen is to identify bacterial surface products that mediate uptake of the organism into non-phagocytic cells. The first bacterial product to be identified in this way is the invasin protein of Yersinia pseudotuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/57\">",
"     57",
"    </a>",
"    ]. In the early 1990s, a similar approach was used to identify a protein (known as mycobacterial cell entry protein, or Mce1A) that conferred upon a nonpathogenic E. coli, an ability to invade HeLa cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/58\">",
"     58",
"    </a>",
"    ]. The significance of M. tuberculosis entering epithelial cells in TB pathogenesis is not clear; most studies examining M. tuberculosis-mammalian cell interactions focus on professional phagocytic cells (macrophages and dendritic cells). It should be noted, however, that the initial site of lung infection by M. tuberculosis is the alveolar air space, which is composed of type I and type II pneumocytes; these are epithelial cells. Type I cells comprise about 96 percent of the alveolar surface area; type II cells cover about 4 percent of the surface area but comprise 60 percent of all the alveolar epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, M. tuberculosis is most likely to encounter and enter pneumocytes before they are taken up by alveolar macrophages. Little is known about the in vivo interaction of M. tuberculosis with alveolar epithelial cells.",
"   </p>",
"   <p>",
"    Mce1A is now known to be located in a 13-gene operon containing genes encoding integral cell wall proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/46\">",
"     46",
"    </a>",
"    ]. Disruption of this operon leads to enhanced virulence of this mutant compared to wild type in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. This observation may relate to M. tuberculosis's ability to establish latent infection in vivo (see below).",
"   </p>",
"   <p>",
"    There are three homologues of mce1 operon (mce2, mce3, mce4) elsewhere in the chromosome arranged in the same manner as the mce1 operon. Phylogenomic analyses of the mce operons suggest that they may encode ATP binding cassette (ABC) transporters which may be involved in lipid importation, and mce4 may play a role in cholesterol import [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A functional disruption of a fatty acyl-coenzyme A (CoA) synthetase gene fadD5 in the mce1 operon caused the mutant to become attenuated in mice and to exhibit diminished growth in minimum medium supplied with mycolic acid as the only carbon source [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/64\">",
"     64",
"    </a>",
"    ]. This led to a hypothesis that live M. tuberculosis may recycle mycolic acids from dying M. tuberculosis inside granulomas for their long-term persistence in a host [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/64\">",
"     64",
"    </a>",
"    ]. As noted below, lipids are a crucial carbon source of energy in vitro. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43289?source=see_link\">",
"     \"Immunology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences in structure, composition, and metabolism of the cell wall lipid molecules contribute to differences in clinical outcome in mammalian hosts. In vivo, M. tuberculosis metabolizes lipids rather than carbohydrates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/55,65\">",
"     55,65",
"    </a>",
"    ]. This shift occurs via a bypass system (glyoxylate shunt) in the Krebs cycle when carbon substrates for glycolysis become limited. The enzymes involved are isocitrate lyases 1 and 2",
"    <span class=\"nowrap\">",
"     (ICL1/2),",
"    </span>",
"    which allow the utilization of fatty acids as a sole carbon source [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43289?source=see_link\">",
"     \"Immunology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The M. tuberculosis cell wall contains three classes of mycolic acids: alpha, keto, and methoxy mycolates. The relative composition of oxygenated mycolates influences growth of M. tuberculosis inside macrophages and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/68\">",
"     68",
"    </a>",
"    ]. An M. tuberculosis mutant lacking trans cyclopropane rings (cmaA2 mutant) in its methoxy and keto-mycolic acids becomes hypervirulent in the mouse model of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/69\">",
"     69",
"    </a>",
"    ]. On the other hand, another cyclopropane synthase gene mutant (pcaA) lacking cis cyclopropane rings in its alpha-mycolates is attenuated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/70\">",
"     70",
"    </a>",
"    ]. Other lipid molecules shown to have an effect on innate and adaptive immune response includes lipoglycans, sulfolipids, and phthiocerol dimycocerosate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/55,71-73\">",
"     55,71-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of signature-tagged transposon mutagenesis to create M. tuberculosis mutants has identified several candidate genes associated with virulence in the mouse model; these have included genes encoding protein secretion systems [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/74\">",
"     74",
"    </a>",
"    ] as well as products involved in lipid biosynthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/75\">",
"     75",
"    </a>",
"    ]. M. tuberculosis secretion systems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESX-1 system, a secretion system involved in the secretion of immunodominant proteins ESAT-6 and CFP-10, has been shown to promote escape of M. tuberculosis into the cytoplasm [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/74,76,77\">",
"       74,76,77",
"      </a>",
"      ]. This secretion system is encoded by an M. tuberculosis chromosome locus called the region of difference (RD-1). RD-1 gene mutants of M. tuberculosis demonstrate macrophage growth attenuation in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. In addition, the RD-1 locus is absent in all BCG vaccine strains, which is believed to be the basis for the attenuation of BCG. ESX-1 homologues have been identified in other pathogenic and nonpathogenic bacteria, and its role in pathogenesis is not fully understood.",
"     </li>",
"     <li>",
"      Sec secretion system (also called the general secretion pathway), which is an essential secretion pathway found in all bacterial species.",
"     </li>",
"     <li>",
"      The twin arginine transporter (TAT), which translocates across the plasma membrane protein substrates with double arginine residues at the N-terminus. Its role in pathogenesis in Mycobacteria is not certain, but the same system found in other pathogens, such as Pseudomonas aeruginosa, enterohemorrhagic E. coli, Legionella pneumophila, is required for virulence [",
"      <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/80-82\">",
"       80-82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Factors associated with intracellular survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mice, M. tuberculosis can be observed inside alveolar macrophages and dendritic cells in the lungs 14 days after aerosol infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/83\">",
"     83",
"    </a>",
"    ]. M. tuberculosis enters these cells after binding to a variety of receptors on these cells, including C-type lectin receptors (mannose receptor, DC-SIGN), scavenger receptors, and complement receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/84\">",
"     84",
"    </a>",
"    ]. It is believed that the engagement of certain receptors can determine the intracellular fate of M. tuberculosis.",
"   </p>",
"   <p>",
"    In addition, M. tuberculosis lipids, including lipoarabinomannan, lipomannans, phosphatidylinositol mannosides, and a 19-kdal lipoprotein, are considered pathogen-associated molecular pattern (PAMP) molecules recognized by toll-like receptor 2 (TLR-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Engagement of these ligands by TLR-2 on macrophages induces a proinflammatory response, including the expression of tumor necrosis factor (TNF-a), interleukin 6 (IL-6), IL-1b, and IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/71,87\">",
"     71,87",
"    </a>",
"    ]. TLR-4 may also engage M. tuberculosis PAMPs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Different clinical strains of M. tuberculosis have been shown to induce distinct patterns of proinflammatory response after engaging these receptors on macrophages, which may determine the clinical outcome of an infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once inside the phagosomal compartment, M. tuberculosis may inhibit the maturation of the phagosome. Phagosomal maturation requires conversion of Rab5 into GTP-bound Rab7 and the generation of phosphatidylinositol 3-phosphate (PI3P) in the phagosomal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. M. tuberculosis products can inhibit these processes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Thus, from the very early phase of infection, M. tuberculosis can initiate control of its intracellular fate.",
"   </p>",
"   <p>",
"    Once M. tuberculosis establishes an infection, another important pathogenic feature is the ability of the organism to establish latent infection, which can then give rise to reactivation disease. Since reactivation tuberculosis is the most common form of the disease, bacterial factors associated with latency are considered important virulence factors.",
"   </p>",
"   <p>",
"    In the 1950s and 1960s, investigators developed a mouse model to study latency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. Mice were intravenously infected with M. tuberculosis and immediately treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    for 12 weeks. Cultures of the animal tissues for up to six weeks following completion of the treatment were negative, but nearly one-third of the animals developed TB after about 12 weeks and two-thirds developed disease after about 24 weeks. It is not clear how representative this model is for latent M. tuberculosis infection in humans. Several variants of this model known as the Cornell model have been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/98\">",
"     98",
"    </a>",
"    ]. The model is highly dependent on the parameters used to establish latency and each version of the model has its own set of limitations.",
"   </p>",
"   <p>",
"    An in vitro model has been developed that mimics the physiologic state of M. tuberculosis during latency in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/99\">",
"     99",
"    </a>",
"    ]. When M. tuberculosis is grown under microaerophilic conditions, a state called nonreplicating, persistent (NRP1) is produced and glycine dehydrogenase activity is induced. In contrast, growth under anaerobic conditions produces a state called NRP2 in which glycine dehydrogenase activity decreases, but the organism still survives as long as the loss of oxygen occurred slowly and it passed through the NRP1 stage for a period of time. When oxygen is reintroduced to organisms grown anaerobically, the pathogen goes out of the NRP2 state. Such an in vitro system could potentially be used to examine differential gene expression and thus to identify bacterial factors specifically required under these growth conditions.",
"   </p>",
"   <p>",
"    Bacterial survival in stationary phase growth can be used as an in vitro model for studying intracellular persistence. A sigma factor gene sigF has been identified in M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/100\">",
"     100",
"    </a>",
"    ]. This gene is a homologue of alternate sigma factor gene (rpoS), which is important for stationary phase survival of E. coli and Salmonella spp. In M. tuberculosis, sigF is expressed during stationary phase, nitrogen depletion, and cold shock, but not during exponential phase growth.",
"   </p>",
"   <p>",
"    One study identified at least seven proteins specifically expressed during the stationary phase growth of M. tuberculosis; the predominant expressed protein was an alpha-crystallin-like heat shock protein (acr) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/101\">",
"     101",
"    </a>",
"    ]. Acr transcript was also induced in M. tuberculosis inside macrophages; acr gene replacement by homologous recombination in M. tuberculosis H37Rv led to impaired growth of the organism inside mouse bone marrow-derived macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/102\">",
"     102",
"    </a>",
"    ]. Thus, acr appears to be important for intracellular survival and replication. Since alpha-crystallin heat shock protein is found in a variety of cell types, its specific role in the observed phenotype of M. tuberculosis needs further elucidation.",
"   </p>",
"   <p>",
"    Several investigators have reported that isocitrate lyase (icl), an enzyme essential for fatty acid metabolism, is specifically upregulated during growth of M. tuberculosis inside macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/66,103,104\">",
"     66,103,104",
"    </a>",
"    ]. There are two icl genes in M. tuberculosis; the predicted proteins are 27 percent identical. In a mouse model of M. tuberculosis infection, deletion of both icl genes led to complete impairment of intracellular replication and rapid elimination of the double mutant from the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above studies suggest that bacterial latency is associated with a hypoxic state in the host. Using a whole genome microarray, a large number of genes that are induced under defined hypoxic conditions were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/106\">",
"     106",
"    </a>",
"    ]. One of these genes was found to be a transcriptional regulator involved in the induction of acr, dosR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/107\">",
"     107",
"    </a>",
"    ]. Whether dosR is essential for M. tuberculosis to establish latent infection or is merely a \"housekeeping\" stress response regulator for the bacillus to respond to a hypoxic condition has yet to be determined. The dosR genes are also present in non-tuberculous mycobacteria (NTM) and may contribute to the cross protection against TB afforded by prior NTM infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. tuberculosis has a particular predilection for the lungs. In immunocompetent mice, virulent strains of M. tuberculosis grow progressively in the lungs but not in the spleen or liver [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/109\">",
"     109",
"    </a>",
"    ]. Even in severe combined immunodeficient (SCID) mice, M. bovis BCG (a relatively avirulent (vaccine) strain) grows faster in the lungs than in other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/110\">",
"     110",
"    </a>",
"    ]. In the mouse model, fewer organisms are required to establish a lung lesion by the inhalation than by intravenous challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/109\">",
"     109",
"    </a>",
"    ]. None of the other pathogenic Mycobacterium species appears to share this tissue tropism. The factors associated with M. tuberculosis that facilitate this unique characteristic are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differences in virulence of clinical isolates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotyping of M. tuberculosis isolates has demonstrated a number of clades that account for a large proportion of new TB cases in different geographic regions, suggesting that such strains may be more virulent than others. M. tuberculous lineages have been associated with clinical manifestations of disease. In one study, for example, East Asian lineage was less likely to be associated with extrapulmonary tuberculosis than Euro-American, Indo-Oceanic, or East-African Indian lineage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/111\">",
"     111",
"    </a>",
"    ]. Improved understanding of the role of MTB lineages may provide insights into pathogenicity, infectiousness, progression from infection to active disease, and, perhaps, response to treatment.",
"   </p>",
"   <p>",
"    The W-Beijing family of M. tuberculosis strains has a global distribution and appears to have a selective advantage facilitating rapid expansion in regions with high background TB incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. The biological reasons for this observation are not fully understood. These strains have been documented to cause outbreaks involving multidrug resistant organisms, although in some regions the majority of W-Beijing strains remain drug susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. M. tuberculosis Beijing genotype strains appear capable of withstanding tuberculosis treatment, even in the absence of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/117\">",
"     117",
"    </a>",
"    ]. W-Beijing strains have been associated with extrathoracic disease and HIV infection, although it is not clear whether HIV infection has contributed to the emergence of these strains [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/115,118,119\">",
"     115,118,119",
"    </a>",
"    ]. In experimental animal models, these strains were highly virulent and BCG vaccination was not protective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/120-122\">",
"     120-122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another strain called CB3.3 caused over 10 percent of new TB cases in New York City between 1992 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/123\">",
"     123",
"    </a>",
"    ]. This strain was found to be resistant to reactive nitrogen intermediates (RNI) generated in vitro by acidified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/123\">",
"     123",
"    </a>",
"    ]. A strain called CDC1551, also found to be resistant to RNI and reactive oxygen intermediates (ROI), caused a large outbreak in a rural area near the Kentucky-Tennessee border in 1994-96 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/124,125\">",
"     124,125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another strain called PG004, responsible for a large cluster of TB cases in one northern California community, was not resistant to these effector molecules. Instead, in mice this strain produced relatively mild lung disease, in which loosely organized granulomas apparently failed to limit the spread of infection and allowed the escape of M. tuberculosis into alveolar air spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/126\">",
"     126",
"    </a>",
"    ]. This study suggested that an M. tuberculosis strain that causes mild lung disease may allow individuals with subclinical disease more time to spread infection in the population. Therefore, such strains would be overly represented in a community. This demonstrates that the predominance of an M. tuberculosis strain in a community is not necessarily a marker of enhanced pathogenicity (eg, transmissibility is not equivalent to virulence).",
"   </p>",
"   <p>",
"    A large school outbreak in the United Kingdom was caused by an M. tuberculosis strain called CH in 2001. Among 254 newly-infected children, 77 developed active disease within a year of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reasons why some lineages cause large outbreaks of rapidly progressive disease and others cause reactivation tuberculosis are poorly understood.",
"   </p>",
"   <p>",
"    The biological &ldquo;fitness cost&rdquo; of drug-resistant M. tuberculosis may be influenced by compensatory mutations. Previously, an experimental model showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance in M. tuberculosis was associated with competitive fitness cost and that resistant isolates from patients with prolonged treatment exhibited no fitness cost [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/128\">",
"     128",
"    </a>",
"    ]. However subsequently many clinical multidrug-resistant strains have been shown to have mutations in the RNA polymerase gene associated with high competitive fitness in vitro and high fitness in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/129\">",
"     129",
"    </a>",
"    ]. In regions of the world with a high prevalence of MDR TB, up to 30 percent of their MDR isolates had such mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HOST FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetic susceptibility to infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic analysis of sibling pairs has been used to evaluate putative genetic markers for enhanced susceptibility to tuberculosis (TB) in populations in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/130\">",
"     130",
"    </a>",
"    ]. Possible markers on chromosomes 15q and Xq were identified; the investigators speculate that finding a susceptibility gene on an X chromosome may partially explain the increased incidence of TB in males in some populations.",
"   </p>",
"   <p>",
"    In a mouse model, a locus on chromosome 19 was found to regulate replication of M. tuberculosis in the lungs of",
"    <span class=\"nowrap\">",
"     DBA/2",
"    </span>",
"    mice that die rapidly of TB compared to",
"    <span class=\"nowrap\">",
"     C57BL/6",
"    </span>",
"    mice that are more resistant to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/131\">",
"     131",
"    </a>",
"    ]. In a second study in a mouse model, a single isoform of the intracellular pathogen resistance 1 gene (Ipr1) was found to be responsible for the increased resistance to M. tuberculosis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/132\">",
"     132",
"    </a>",
"    ]. Resistance was characterized by smaller lung lesions containing fewer macrophages, slower M. tuberculosis growth in macrophages, and death of M. tuberculosis-infected macrophages by apoptosis rather than necrosis.",
"   </p>",
"   <p>",
"    The closest human homologue to lpr1 is SP110. A study of families from Guinea-Bissau and the Republic of Guinea, identified three polymorphisms in the SP110 gene that are associated with susceptibility to tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acquired susceptibility to infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators examined the interferon-gamma (IFN-gamma) response pathway in three patients with severe, unexplained nontuberculous mycobacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/54/22378/abstract/134\">",
"     134",
"    </a>",
"    ]. In all three patients, IFN-gamma was undetectable following stimulation of whole blood, but was detectable when stimulated in the absence of the patients' own plasma. An autoantibody against IFN-gamma was isolated from the patients' plasma and was found to be capable of blocking the upregulation of TNF-alpha production in response to endotoxin, in blocking induction of IFN-gamma-inducible genes, and in inhibiting upregulation of HLA class II expression on peripheral blood mononuclear cells (PBMCs). These acquired defects in the IFN-gamma pathway may explain unusual susceptibilities to intracellular pathogens, including mycobacteria, in patients without underlying, genetically determined immunologic defects.",
"   </p>",
"   <p>",
"    All of the host genes associated with TB susceptibility account for a tiny fraction of all tuberculosis cases identified in the world. The most important host factor that determines TB susceptibility to TB is HIV co-infection, followed by other immunosuppressive conditions, including cancer, diabetes, and immunosuppressive medications. Environmental factors, such as crowding, low socioeconomic status, poor access to healthcare, and family history, also contribute substantially to the incidence of TB worldwide, and these are important to understanding TB pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13826771\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhalation of Mycobacterium tuberculosis and deposition in the lungs leads to one of four possible outcomes: immediate clearance of the organism, rapid progression to active disease (primary disease), or latent infection (with or without subsequent reactivation disease). (See",
"      <a class=\"local\" href=\"#H13826069\">",
"       'Natural history of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cell envelope is a distinguishing feature of the organisms belonging to the genus Mycobacterium. Mycolic acid is the major constituent of the cell envelope; this structure defines the genus. The mycolic acid structure confers the ability to resist destaining by acid alcohol after being stained by certain aniline dyes, leading to the term acid fast bacillus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cell envelope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microscopy to detect acid fast bacillus (using Ziehl-Neelsen or Kinyoun stain) is a commonly used procedure for the rapid diagnosis of tuberculosis (TB); a specimen must contain at least 10(4) colony forming units",
"      <span class=\"nowrap\">",
"       (CFU)/mL",
"      </span>",
"      to yield a positive smear. Microscopy of specimens stained with a fluorochrome dye (such as auramine O provides) is a more sensitive and efficient technique. Microscopic detection of mycobacteria does not distinguish M. tuberculosis from nontuberculous mycobacteria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Staining characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The slow growth rate is a distinguishing feature of M. tuberculosis. In artificial media and animal tissues, the generation time is about 20 to 24 hours, which means that cultures may take from two to six weeks for detectable growth, depending on the cultivation systems used for laboratory isolation (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Isolation in the laboratory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the organism is isolated, identification is based upon morphologic and biochemical characteristics, although nucleic acid-based detection methods have obviated many of the conventional tests. The niacin, nitrate reductase, and catalase tests are the three biochemical tests most frequently used to distinguish M. tuberculosis from other mycobacterial species (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Identification of the organism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following virulence factors have been described: mycolic acid glycolipids and trehalose dimycolate (which can elicit granuloma formation in animal tissue), catalase-peroxidase (which resists the host cell oxidative response), sulfatides and trehalose dimycolate (which can trigger toxicity in animal models), and lipoarabinomannan (LAM) (which can induce cytokines and resist host oxidative stress). Molecular biology techniques have identified many other gene products that may be involved in the ability of M. tuberculosis to enter cells, resist intracellular killing, establish persistence, and come out of latency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Virulence factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies have revealed a few key M. tuberculosis lineages to be overly represented or clustered in certain communities. Such occurrences may relate to these strains&rsquo; distinct biological &ldquo;fitness&rdquo; or transmissibility. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differences in virulence of clinical isolates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/1\">",
"      Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982; 125:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/2\">",
"      National action plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41:5.",
"     </a>",
"    </li>",
"    <li>",
"     Rich, A. The Pathogenesis of Tuberculosis, Charles C Thomas, Springfield 1951.",
"    </li>",
"    <li>",
"     Dubos, R, Dubos, J. The White Plague: Tuberculosis, Man, and Society, Little, Brown, Boston 1952.",
"    </li>",
"    <li>",
"     Lurie, MB. Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defense Mechanisms, Harvard University Press, Cambridge 1964.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/6\">",
"      Collins FM, Campbell SG. Immunity to intracellular bacteria. Vet Immunol Immunopathol 1982; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     Dannenberg, AM Jr, Tomashefski, JF Jr. Pathogenesis of pulmonary tuberculosis. In: Pulmonary Diseases and Disorders, 2nd ed, Fishman, AP (Eds), McGraw-Hill, New York 1988. Vol 3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/8\">",
"      Barnes, HL, Barnes, IR. The duration of life in pulmonary tuberculosis with cavity. Am Rev Tuberculosis 1928; 18:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/9\">",
"      Heimbeck J. The infection of tuberculosis. Acta Med Scand 1930; 74:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/10\">",
"      Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012; 54:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/11\">",
"      Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/12\">",
"      van Soolingen D, Hoogenboezem T, de Haas PE, et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol 1997; 47:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/13\">",
"      McNeil MR, Brennan PJ. Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res Microbiol 1991; 142:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/14\">",
"      Bhanot N, Zaman MM. An immigrant with a painful swelling in his back. Clin Infect Dis 2007; 44:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/15\">",
"      Allen BW, Mitchison DA. Counts of viable tubercle bacilli in sputum related to smear and culture gradings. Med Lab Sci 1992; 49:94.",
"     </a>",
"    </li>",
"    <li>",
"     Kent, PT, Kubica, GP. Public health mycobacteriology: A guide for the level III laboratory. Centers for Disease Control, US PHS. 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/17\">",
"      Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161:1376.",
"     </a>",
"    </li>",
"    <li>",
"     Hanna, BA. Diagnosis of tuberculosis by microbiologic techniques. In: Tuberculosis, Rom, WN, Garay, S (Eds), Little, Brown, Boston 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/19\">",
"      Roberts GD, Goodman NL, Heifets L, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol 1983; 18:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/20\">",
"      Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/21\">",
"      D'Amato RF, Isenberg HD, Hochstein L, et al. Evaluation of the Roche Septi-Chek AFB system for recovery of mycobacteria. J Clin Microbiol 1991; 29:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/22\">",
"      Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the Mycobacteria Growth Indicator Tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol 1997; 35:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/23\">",
"      Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol 2006; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/24\">",
"      Magee JG, Freeman R, Barrett A. Enhanced speed and sensitivity in the cultural diagnosis of pulmonary tuberculosis with a continuous automated mycobacterial liquid culture (CAMLiC) system. J Med Microbiol 1998; 47:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/25\">",
"      Kas��rov LB, Moat AG. Metabolism of nicotinamide adenine dinucleotide in human and bovine strainsof Mycobacterium tuberculosis. J Bacteriol 1972; 110:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/26\">",
"      Vestal AL, Kubica GP. Differential identification of mycobacteria. 3. Use of thiacetazone, thiophen-2-carboxylic acid hydrazide, and triphenyltetrazolium chloride. Scand J Respir Dis 1967; 48:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/27\">",
"      Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/28\">",
"      CANETTI G, RIST N, GROSSET J. [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris) 1963; 27:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/29\">",
"      CANETTI G, FROMAN S, GROSSET J, et al. MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. Bull World Health Organ 1963; 29:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/30\">",
"      Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 1998; 36:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/31\">",
"      Yajko DM, Madej JJ, Lancaster MV, et al. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol 1995; 33:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/32\">",
"      Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol 2000; 38:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/33\">",
"      Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/34\">",
"      Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/35\">",
"      Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Tuberculosis diagnostics: Automated DNA test. file://www.who.int/tb/features_archive/new_rapid_test/en/ (Accessed on May 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/37\">",
"      Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/38\">",
"      Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/39\">",
"      Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/40\">",
"      Banaiee N, Bobadilla-Del-Valle M, Bardarov S Jr, et al. Luciferase reporter mycobacteriophages for detection, identification, and antibiotic susceptibility testing of Mycobacterium tuberculosis in Mexico. J Clin Microbiol 2001; 39:3883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/41\">",
"      Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000; 44:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/42\">",
"      McNerney R, Kiepiela P, Bishop KS, et al. Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin. Int J Tuberc Lung Dis 2000; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/43\">",
"      Albert H, Muzaffar R, Mole RJ, Trollip AP. Use of the FASTPlaque test for TB diagnosis in low-income countries. Int J Tuberc Lung Dis 2002; 6:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/44\">",
"      Muzaffar R, Batool S, Aziz F, et al. Evaluation of the FASTPlaqueTB assay for direct detection of Mycobacterium tuberculosis in sputum specimens. Int J Tuberc Lung Dis 2002; 6:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/45\">",
"      Kalantri S, Pai M, Pascopella L, et al. Bacteriophage- based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta- analysis. BMC Infect Dis 2005; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/46\">",
"      Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/47\">",
"      Ross BC, Raios K, Jackson K, Dwyer B. Molecular cloning of a highly repeated DNA element from Mycobacterium tuberculosis and its use as an epidemiological tool. J Clin Microbiol 1992; 30:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/48\">",
"      Groenen PM, Bunschoten AE, van Soolingen D, van Embden JD. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for strain differentiation by a novel typing method. Mol Microbiol 1993; 10:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/49\">",
"      Ramakrishnan L, Federspiel NA, Falkow S. Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 2000; 288:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/50\">",
"      Chan J, Fan XD, Hunter SW, et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/51\">",
"      Rastogi N, David HL. Mechanisms of pathogenicity in mycobacteria. Biochimie 1988; 70:1101.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart-Tull, DE. Immunologically important constituents of Mycobacteria: Adjuvants. In: Biology of the Mycobacteria, Ratledge, C, Stanford, J (Eds), Academic Press, London 1983. Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/53\">",
"      Barksdale L, Kim KS. Mycobacterium. Bacteriol Rev 1977; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/54\">",
"      Goren MB, Brokl O, Schaefer WB. Lipids of putative relevance to virulence in Mycobacterium tuberculosis: correlation of virulence with elaboration of sulfatides and strongly acidic lipids. Infect Immun 1974; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/55\">",
"      BLOCH H, SEGAL W. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol 1956; 72:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/56\">",
"      Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/57\">",
"      Isberg RR, Falkow S. A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12. Nature 1985; 317:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/58\">",
"      Arruda S, Bomfim G, Knights R, et al. Cloning of an M. tuberculosis DNA fragment associated with entry and survival inside cells. Science 1993; 261:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/59\">",
"      Castranova V, Rabovsky J, Tucker JH, Miles PR. The alveolar type II epithelial cell: a multifunctional pneumocyte. Toxicol Appl Pharmacol 1988; 93:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/60\">",
"      Shimono N, Morici L, Casali N, et al. Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. Proc Natl Acad Sci U S A 2003; 100:15918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/61\">",
"      Uchida Y, Casali N, White A, et al. Accelerated immunopathological response of mice infected with Mycobacterium tuberculosis disrupted in the mce1 operon negative transcriptional regulator. Cell Microbiol 2007; 9:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/62\">",
"      Casali N, Riley LW. A phylogenomic analysis of the Actinomycetales mce operons. BMC Genomics 2007; 8:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/63\">",
"      Pandey AK, Sassetti CM. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A 2008; 105:4376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/64\">",
"      Dunphy KY, Senaratne RH, Masuzawa M, et al. Attenuation of Mycobacterium tuberculosis functionally disrupted in a fatty acyl-coenzyme A synthetase gene fadD5. J Infect Dis 2010; 201:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/65\">",
"      Collins DM. In search of tuberculosis virulence genes. Trends Microbiol 1996; 4:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/66\">",
"      McKinney JD, H&ouml;ner zu Bentrup K, Mu&ntilde;oz-El&iacute;as EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/67\">",
"      Dubnau E, Chan J, Mohan VP, Smith I. responses of mycobacterium tuberculosis to growth in the mouse lung. Infect Immun 2005; 73:3754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/68\">",
"      Yuan Y, Zhu Y, Crane DD, Barry CE 3rd. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol Microbiol 1998; 29:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/69\">",
"      Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med 2005; 201:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/70\">",
"      Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/71\">",
"      Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999; 285:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/72\">",
"      Camacho LR, Constant P, Raynaud C, et al. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J Biol Chem 2001; 276:19845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/73\">",
"      Cox JS, Chen B, McNeil M, Jacobs WR Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999; 402:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/74\">",
"      DiGiuseppe Champion PA, Cox JS. Protein secretion systems in Mycobacteria. Cell Microbiol 2007; 9:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/75\">",
"      Camacho LR, Ensergueix D, Perez E, et al. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999; 34:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/76\">",
"      Guinn KM, Hickey MJ, Mathur SK, et al. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol 2004; 51:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/77\">",
"      van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007; 129:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/78\">",
"      Brodin P, Majlessi L, Marsollier L, et al. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. Infect Immun 2006; 74:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/79\">",
"      Stanley SA, Raghavan S, Hwang WW, Cox JS. Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system. Proc Natl Acad Sci U S A 2003; 100:13001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/80\">",
"      Voulhoux R, Ball G, Ize B, et al. Involvement of the twin-arginine translocation system in protein secretion via the type II pathway. EMBO J 2001; 20:6735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/81\">",
"      Pradel N, Ye C, Livrelli V, et al. Contribution of the twin arginine translocation system to the virulence of enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2003; 71:4908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/82\">",
"      Rossier O, Cianciotto NP. The Legionella pneumophila tatB gene facilitates secretion of phospholipase C, growth under iron-limiting conditions, and intracellular infection. Infect Immun 2005; 73:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/83\">",
"      Wolf AJ, Linas B, Trevejo-Nu&ntilde;ez GJ, et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 2007; 179:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/84\">",
"      Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Annu Rev Pathol 2012; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/85\">",
"      Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999; 96:14459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/86\">",
"      Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/87\">",
"      Heldwein KA, Fenton MJ. The role of Toll-like receptors in immunity against mycobacterial infection. Microbes Infect 2002; 4:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/88\">",
"      Means TK, Wang S, Lien E, et al. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999; 163:3920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/89\">",
"      Means TK, Jones BW, Schromm AB, et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 2001; 166:4074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/90\">",
"      Rocha-Ram&iacute;rez LM, Estrada-Garc&iacute;a I, L&oacute;pez-Mar&iacute;n LM, et al. Mycobacterium tuberculosis lipids regulate cytokines, TLR-2/4 and MHC class II expression in human macrophages. Tuberculosis (Edinb) 2008; 88:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/91\">",
"      Philips JA. Mycobacterial manipulation of vacuolar sorting. Cell Microbiol 2008; 10:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/92\">",
"      Vergne I, Chua J, Lee HH, et al. Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2005; 102:4033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/93\">",
"      Bach H, Papavinasasundaram KG, Wong D, et al. Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. Cell Host Microbe 2008; 3:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/94\">",
"      Sun J, Wang X, Lau A, et al. Mycobacterial nucleoside diphosphate kinase blocks phagosome maturation in murine RAW 264.7 macrophages. PLoS One 2010; 5:e8769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/95\">",
"      MCCUNE RM Jr, TOMPSETT R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956; 104:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/96\">",
"      MCCUNE RM Jr, MCDERMOTT W, TOMPSETT R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/97\">",
"      McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/98\">",
"      Scanga CA, Mohan VP, Joseph H, et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/99\">",
"      Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/100\">",
"      DeMaio J, Zhang Y, Ko C, et al. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1996; 93:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/101\">",
"      Yuan Y, Crane DD, Barry CE 3rd. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 1996; 178:4484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/102\">",
"      Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A 1998; 95:9578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/103\">",
"      H&ouml;ner Zu Bentrup K, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999; 181:7161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/104\">",
"      Graham JE, Clark-Curtiss JE. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci U S A 1999; 96:11554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/105\">",
"      Mu&ntilde;oz-El&iacute;as EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 2005; 11:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/106\">",
"      Sherman DR, Voskuil M, Schnappinger D, et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A 2001; 98:7534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/107\">",
"      Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003; 48:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/108\">",
"      Lin MY, Reddy TB, Arend SM, et al. Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. Infect Immun 2009; 77:5071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/109\">",
"      PIERCE CH, DUBOS RJ, SCHAEFER WB. Multiplication and survival of tubercle bacilli in the organs of mice. J Exp Med 1953; 97:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/110\">",
"      North RJ, Izzo AA. Mycobacterial virulence. Virulent strains of Mycobacteria tuberculosis have faster in vivo doubling times and are better equipped to resist growth-inhibiting functions of macrophages in the presence and absence of specific immunity. J Exp Med 1993; 177:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/111\">",
"      Click ES, Moonan PK, Winston CA, et al. Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis. Clin Infect Dis 2012; 54:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/112\">",
"      Cowley D, Govender D, February B, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis 2008; 47:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/113\">",
"      Yang C, Luo T, Sun G, et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis 2012; 55:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/114\">",
"      Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis 1999; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/115\">",
"      Marais BJ, Victor TC, Hesseling AC, et al. Beijing and Haarlem genotypes are overrepresented among children with drug-resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol 2006; 44:3539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/116\">",
"      Buu TN, Huyen MN, van Soolingen D, et al. The Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment failure in Vietnam. Clin Infect Dis 2010; 51:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/117\">",
"      Parwati I, Alisjahbana B, Apriani L, et al. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis 2010; 201:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/118\">",
"      Kong Y, Cave MD, Zhang L, et al. Association between Mycobacterium tuberculosis Beijing/W lineage strain infection and extrathoracic tuberculosis: Insights from epidemiologic and clinical characterization of the three principal genetic groups of M. tuberculosis clinical isolates. J Clin Microbiol 2007; 45:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/119\">",
"      Caws M, Thwaites G, Stepniewska K, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. J Clin Microbiol 2006; 44:3934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/120\">",
"      Manca C, Tsenova L, Freeman S, et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005; 25:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/121\">",
"      Tsenova L, Ellison E, Harbacheuski R, et al. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis 2005; 192:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/122\">",
"      Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu&eacute;rin mutants that secrete listeriolysin. J Clin Invest 2005; 115:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/123\">",
"      Friedman CR, Quinn GC, Kreiswirth BN, et al. Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J Infect Dis 1997; 176:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/124\">",
"      Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998; 338:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/125\">",
"      Firmani MA, Riley LW. Mycobacterium tuberculosis CDC1551 is resistant to reactive nitrogen and oxygen intermediates in vitro. Infect Immun 2002; 70:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/126\">",
"      Cantrell SA, Pascopella L, Flood J, et al. Community-wide transmission of a strain of Mycobacterium tuberculosis that causes reduced lung pathology in mice. J Med Microbiol 2008; 57:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/127\">",
"      Newton SM, Smith RJ, Wilkinson KA, et al. A deletion defining a common Asian lineage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A 2006; 103:15594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/128\">",
"      Gagneux S, Long CD, Small PM, et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/129\">",
"      Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012; 44:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/130\">",
"      Bellamy R, Beyers N, McAdam KP, et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A 2000; 97:8005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/131\">",
"      Mitsos LM, Cardon LR, Ryan L, et al. Susceptibility to tuberculosis: a locus on mouse chromosome 19 (Trl-4) regulates Mycobacterium tuberculosis replication in the lungs. Proc Natl Acad Sci U S A 2003; 100:6610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/132\">",
"      Pan H, Yan BS, Rojas M, et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005; 434:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/133\">",
"      Tosh K, Campbell SJ, Fielding K, et al. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A 2006; 103:10364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/54/22378/abstract/134\">",
"      Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 2005; 115:2480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8023 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22378=[""].join("\n");
var outline_f21_54_22378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13826771\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13826069\">",
"      NATURAL HISTORY OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13826076\">",
"      Primary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13826083\">",
"      Reactivation disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cell envelope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Staining characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Growth characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Isolation in the laboratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Identification of the organism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug susceptibility tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Factors associated with intracellular survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differences in virulence of clinical isolates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HOST FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetic susceptibility to infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acquired susceptibility to infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13826771\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43289?source=related_link\">",
"      Immunology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_54_22379="Outcomes of Rx male breast Ca";
var content_f21_54_22379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcomes of treatment for male breast cancer in 1986 men in the SEER* database, 1988-2001",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Disease stage",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Disease specific survival, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Overall survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5 yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Calculated from the SEER database.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Giordano, S et al. Oncologist 2005; 10:471.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22379=[""].join("\n");
var outline_f21_54_22379=null;
var title_f21_54_22380="Revised RECIST criteria only";
var content_f21_54_22380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised Response Evaluation Criteria in Solid Tumors (RECIST) for assessing clinical tumor response",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Response assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        RECIST guideline, version 1.1",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Target lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CR",
"       </td>",
"       <td>",
"        Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to &le;10 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PR",
"       </td>",
"       <td>",
"        &ge;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PD",
"       </td>",
"       <td>",
"        <p>",
"         &ge;20 percent increase of at least 5 mm in the sum of the longest diameters of the target lesions compared with the smallest sum of the longest diameter recorded",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         The appearance of new lesions including those detected by FDG-PET",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SD",
"       </td>",
"       <td>",
"        Neither PR nor PD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Non-target lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CR",
"       </td>",
"       <td>",
"        Disappearance of all non-target lesions and normalization of tumor marker levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IR, SD",
"       </td>",
"       <td>",
"        Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PD",
"       </td>",
"       <td>",
"        <p>",
"         The appearance of one of more new lesions or unequivocal progression.",
"        </p>",
"        <p>",
"         If patient has measurable disease, an increase in the overall level, or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is a SD or PR in target lesions.",
"        </p>",
"        <p>",
"         If no measurable disease, an increase in the overall tumor burden comparable in magnitude to the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread).",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CR: complete response; IR: incomplete response; PD: progressive disease; SD: stable disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Eisenhauer E, et al. Eur J Cancer 2009; 45:228.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22380=[""].join("\n");
var outline_f21_54_22380=null;
var title_f21_54_22381="GUD clinical manifestations";
var content_f21_54_22381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics of infectious causes of genital ulcer disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       GUD syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Etiologic agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Classic ulcer characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Incubation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pain",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adenopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       HSV",
"      </td>",
"      <td>",
"       HSV type 2 in most cases, HSV-1 is less common",
"      </td>",
"      <td>",
"       Multiple small grouped ulcers; erythematous base. Occasionally, single lesions/fissures can be seen",
"      </td>",
"      <td>",
"       2-7 days",
"      </td>",
"      <td>",
"       Usually painful; can be painless or pruritic",
"      </td>",
"      <td>",
"       Reactive painful nodes common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Vesicles can open forming shallow ulcers/erosions which may coalesce",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Syphilis",
"      </td>",
"      <td>",
"       Treponema pallidum",
"      </td>",
"      <td>",
"       Indurated, smooth firm borders",
"      </td>",
"      <td>",
"       7-90 days",
"      </td>",
"      <td>",
"       Usually painless; rarely can be painful",
"      </td>",
"      <td>",
"       Firm, rubbery nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Clean base",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Not tender",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Heals spontaneously",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Regional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Usually singular, although multiple chancres can occur",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Discrete",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Chancroid",
"      </td>",
"      <td>",
"       Haemophilus ducreyi",
"      </td>",
"      <td>",
"       Sharply circumscribed or irregular, ragged undermined edges",
"      </td>",
"      <td>",
"       3-10 days",
"      </td>",
"      <td>",
"       Marked",
"      </td>",
"      <td>",
"       50 percent with inguinal adenopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Not indurated",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Usually unilateral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Base may have gray or yellow exudate",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Often painful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Multiple ulcers",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       May suppurate/rupture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       LGV",
"      </td>",
"      <td>",
"       Chlamydia trachomatis L1-L3",
"      </td>",
"      <td>",
"       Usually not observed",
"      </td>",
"      <td>",
"       5-21 days",
"      </td>",
"      <td>",
"       Usually painless",
"      </td>",
"      <td>",
"       More common in males",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Small and shallow",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Matted clusters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Rapid spontaneous healing",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Unilateral or often bilateral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Large painful fluctuant \"buboe\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Painful groove sign",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Sinus tracts common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Granuloma inguinale",
"      </td>",
"      <td>",
"       Calymmatobacterium granulomatis",
"      </td>",
"      <td>",
"       Extensive, progressive",
"      </td>",
"      <td>",
"       7-90 days",
"      </td>",
"      <td>",
"       Usually painless",
"      </td>",
"      <td>",
"       Pseudobuboes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Granulation-like tissue",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Rolled edges",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22381=[""].join("\n");
var outline_f21_54_22381=null;
var title_f21_54_22382="Difficult airway algorithm";
var content_f21_54_22382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The difficult airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMV: bag-mask ventilation; EGD: extra-glottic device; DL: direct laryngoscopy; FO: fiberoptic method; VL: video laryngoscopy; RSI: rapid sequence intubation; ILMA: intubating laryngeal mask; BNTI: blind nasotracheal intubation.",
"     <br/>",
"     * RSI may require a double set-up. See text for details.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If not used for awake laryngoscopy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management,&nbsp;4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22382=[""].join("\n");
var outline_f21_54_22382=null;
var title_f21_54_22383="Catch-up immunization schedule age 4 months through 6 years";
var content_f21_54_22383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Catch-up immunization schedule for persons aged 4 months through 6 years who start late or who are more than 1 month behind - United States, 2013",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Minimum age for dose 1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Minimum interval between doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Dose 1 to dose 2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 2 to dose 3",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 3 to dose 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 4 to dose 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B*",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        8 weeks (and at least 16 weeks after first dose; minimum age for the final dose is 24 weeks)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Rotavirus",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diphtheria, tetanus, pertussis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks if first dose administered at younger than age 12 months",
"       </td>",
"       <td>",
"        4 weeks",
"        <sup>",
"         &loz;",
"        </sup>",
"        if current age is younger than 12 months",
"       </td>",
"       <td rowspan=\"3\">",
"        8 weeks (as final dose). This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months.",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 weeks (as final dose) if first dose administered at age 12 to 14 months",
"       </td>",
"       <td>",
"        8 weeks (as final dose",
"        <sup>",
"         &loz;",
"        </sup>",
"        ) if current age is 12 months or older and first dose administered at younger than age 12 months and second dose administered at younger than 15 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No further doses needed if first dose administered at age 15 months or older",
"       </td>",
"       <td>",
"        No further doses needed if previous dose administered at age 15 months or older",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Pneumococcal",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks if first dose administered at younger than age 12 months",
"       </td>",
"       <td>",
"        4 weeks if current age is younger than 12 months",
"       </td>",
"       <td rowspan=\"3\">",
"        8 weeks (as final dose). This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months or for high-risk children who received 3 doses at any age.",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 weeks (as final dose for healthy children) if first dose administered at age 12 months or older or current age 24 through 59 months",
"       </td>",
"       <td>",
"        8 weeks (as final dose for healthy children) if current age is 12 months or older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No further doses needed for healthy children if first dose administered at age 24 months or older",
"       </td>",
"       <td>",
"        No further doses needed for healthy children if previous dose administered at age 24 months or older",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Inactivated poliovirus",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &yen;",
"        </sup>",
"        (minimum age 4 years for final dose)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Meningococcal",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        8 weeks",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        See footnote (������)",
"       </td>",
"       <td>",
"        See footnote (������)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Measles, mumps, rubella",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Varicella**",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis A",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above table provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use this table in conjunction with its footnotes and the table of the schedule of recommended childhood immunizations for children 0 through 6 years of age in the United States.",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Hepatitis B (HepB) vaccine:",
"     </strong>",
"     Unvaccinated persons should complete a 3-dose series.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      <strong>",
"       Rotavirus (RV) vaccines:",
"      </strong>",
"      The maximum age for the first dose in the series is 14 weeks, 6 days. Vaccination should not be initiated for infants aged 15 weeks 0 days or older. The maximum age for the final dose in the series is 8 months, 0 days. If RV1 (Rotarix) is administered for the first and second doses, a third dose is not indicated.",
"      <br>",
"       &Delta;",
"       <strong>",
"        Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine:",
"       </strong>",
"       The fifth (booster) dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        <strong>",
"         <em>",
"          Haemophilus influenzae",
"         </em>",
"         type b (Hib) conjugate vaccine:",
"        </strong>",
"        If dose 1 was administered at ages 12 to 14 months, administer booster (as final dose) at least 8 weeks after dose 1. If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax), and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose. If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a final dose at age 12 through 15 months, regardless of Hib vaccine (PRP-T [Hiberix] or PRP-OMP) used for first dose. For unvaccinated children aged 15 months or older, administer only 1 dose; however if the combination Hib-meningococcal conjugate vaccine (Menhibrix [HibMenCY]) is used, two doses, eight weeks apart, should be administered.",
"        <strong>",
"         Vaccination of persons with high-risk conditions:",
"        </strong>",
"        Hib vaccine is not routinely recommended for patients older than 5 years of age. However one dose of Hib vaccine should be administered to unvaccinated or partially vaccinated persons aged 5 years or older who have leukemia, malignant neoplasms, anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, or other immunocompromising conditions.",
"        <br>",
"         &sect;",
"         <strong>",
"          Pneumococcal vaccines:",
"         </strong>",
"         <em>",
"          (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV23]).",
"         </em>",
"         Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.",
"         <strong>",
"          Vaccination of persons with high-risk conditions:",
"         </strong>",
"         For children aged 24 through 71 months with high-risk conditions (listed below) administer 1 dose of PCV13 if 3 doses of PCV were received previously, or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously. Administer PPSV23 at least 8 weeks after the last dose of PCV to children aged 2 years or older with high-risk conditions (listed below). A single revaccination with PPSV23 should be administered after 5 years to children with anatomic or functional asplenia (including sickle cell disease) or an immunocompromising condition. A single dose of PCV13 may be administered to previously unvaccinated children aged 6 through 18 years who have anatomic or functional asplenia (including sickle cell disease), HIV infection or an immunocompromising condition, cochlear implant or cerebrospinal fluid leak. See MMWR 2010; 59 (No. RR-11), available at",
"         <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf\" target=\"_blank\">",
"          www.cdc.gov/mmwr/pdf/rr/rr5911.pdf",
"         </a>",
"         .",
"         <strong>",
"          High-risk conditions for pneumococcal vaccines:",
"         </strong>",
"         1) Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant. 2) Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction). 3) Children with immunocompromising conditions: HIV infection, chronic renal failure and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation, congenital immunodeficiency.",
"         <br>",
"          &yen;",
"          <strong>",
"           Inactivated poliovirus (IPV) vaccine:",
"          </strong>",
"          In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (ie, travel to a polio-endemic region or during an outbreak). If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years. A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. If both oral poliovirus vaccine (OPV) and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.",
"          <br>",
"           &Dagger;",
"           <strong>",
"            Meningococcal conjugate vaccines (MCV):",
"           </strong>",
"           <em>",
"            (Minimum age: 6 weeks for Menhibrix [HibMenCY], 9 months for Menactra [MCV4-D]; 2 years for Menveo [MCV4-CRM]).",
"           </em>",
"           <strong>",
"            Vaccination of persons with high-risk conditions:",
"           </strong>",
"           MCV vaccine is not routinely recommended for healthy children. For children younger than 19 months of age with anatomic or functional asplenia (including sickle cell disease), administer an infant series of HibMenCY at 2, 4, 6, and 12-15 months. For children aged 2 through 18 months with persistent complement component deficiency, administer either an infant series of HibMenCY at 2, 4, 6, and 12 through 15 months or a 2-dose primary series of MCV4-D starting at 9 months, with at least 8 weeks between doses. For children aged 19 through 23 months with persistent complement component deficiency who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of MCV4-D at least 8 weeks apart. For children aged 24 months and older with persistent complement component deficiency or anatomic or functional asplenia (including sickle cell disease), who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of either MCV4-D or MCV4-CRM. MCV4-D (Menactra) should not be administered to a child with asplenia (including sickle cell disease) until 2 years of age and at least 4 weeks after the completion of all PCV13 doses. See MMWR 2011; 60:1391, available at",
"           <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"            www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"           </a>",
"           . For children aged 9 months and older who are residents of or travelers to countries in the African meningitis belt or to the Hajj, administer an age-appropriate formulation and series of MCV4 for protection against serogroups A and W-135. Prior receipt of HibMenCY is not sufficient for children traveling to the meningitis belt or the Hajj. See MMWR 2011; 60:1391,",
"           <br>",
"            available at",
"            <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"             www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"            </a>",
"            . For children who are present during outbreaks caused by a vaccine serogroup, administer or complete an age- and formulation-appropriate series of HibMenCY or MCV4. For booster doses among persons with high-risk conditions refer to",
"            <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm#mening\" target=\"_blank\">",
"             www.cdc.gov/vaccines/pubs/acip-list.htm#mening",
"            </a>",
"            .",
"            <br>",
"             &dagger;",
"             <strong>",
"              Measles, mumps, and rubella (MMR) vaccine:",
"             </strong>",
"             Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.",
"             <br>",
"              **",
"              <strong>",
"               Varicella (VAR) vaccine:",
"              </strong>",
"              The minimum interval between doses is 3 months.",
"              <br>",
"               <font class=\"double_bullet\">",
"                &bull;&bull;",
"               </font>",
"               <strong>",
"                Hepatitis A (Hep A) vaccine:",
"               </strong>",
"               The minimum interval between the two doses is 6 months.",
"               <strong>",
"                Special populations:",
"               </strong>",
"               Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Akinsanya-Beysolow I, Jenkins R, Meissner HC, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013. MMWR Surveill Summ 2013; 62:2. Available at:",
"      <a href=\"file://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf\" target=\"_blank\">",
"       www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf",
"      </a>",
"      (Accessed on February 3, 2013).",
"      <br>",
"       2. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of meningococcal disease. MMWR Recomm Rep 2013; 62:1. Available at:",
"       <a href=\"file:///\" style=\"FONT-STYLE: italic\">",
"        file://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm",
"       </a>",
"       (Accessed on April 1, 2013).",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_54_22383=[""].join("\n");
var outline_f21_54_22383=null;
